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Racial and ethnic disparities related to lung cancer treatments and outcomes are not fully 
understood but may be due to individual or institutional factors. Following established 
national cancer treatment guidelines may improve patients’ quality of life, outcome to 
treatment, and facilitate the eradication of lung cancer. There are limited data on the real-
world treatment of racial/ethnic groups with non-small cell lung cancer (NSCLC) 
according to clinical practice guidelines, therefore this population-based cohort study 
examined the receipt of first line treatment for advanced or metastatic NSCLC according 
to the National Comprehensive Cancer Network (NCCN) practice guidelines. The Social 
Cognitive Theory served as the framework as it focuses on individual cognitive 
influences and self-efficacy. A retrospective analysis of NSCLC patients (> 65 years) was 
conducted using the linked Surveillance, Epidemiology, and End Results (SEER) data 
linked with Medicare.  Logistic regression models were fit to evaluate the relationships 
between patient race/ethnicity and the receipt of treatment according to the guidelines 
within various clinical strata (e.g., histology type, stage of disease). There were no 
significant differences between Caucasians and African Americans in terms of treatment 
consistent with guidelines after controlling for other factors. One limitation to this study 
was the administrative nature of the Medicare database and the limited number of 
Hispanic patients.  This research may contribute to positive social change by supporting a 
deeper understanding of factors that might influence NSCLC treatment selection.  Public 
health initiatives to promote compliance with treatment guidelines can lead to better 
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Chapter 1: Introduction to the Study  
Introduction 
Lung cancer is the second most common cancer in the United States and is a 
major health problem, representing 14% of all new cancers (American Cancer Society 
[ACS], 2018).  It kills more patients than breast cancer, colon cancer, and prostate cancer 
combined (ACS, 2013; Lung Cancer Alliance, 2013, Surveillance Epidemiology End 
Results [SEER], n.d.) and worldwide contributes to more deaths than HIV, tuberculosis, 
and malaria (ACS, 2011).  Lung cancer is a disease of the elderly.  Two out of three 
individuals with lung cancer are 65 years of age or older with a median age at diagnosis 
of 70 years, and less than 2% of lung cancer are diagnosed in individuals younger than 45 
years of age (ACS, 2014).  In 2013, lung cancer was the leading cause of death in men 
and women in the United States, killing over 160,000 individuals (ACS, 2013b; 
American Lung Association [ALA], 2014, SEER, n.d.).  The World Health Organization 
(WHO) predicts the number of new cancers overall will grow from 14 million to more 
than 22 million by 2030 (American Society Clinical Oncology [ASCO], 2014). 
The incidence of lung cancer varies by stage of disease and by race/ethnicity.  
According to the ALA (2010) African American men are diagnosed with lung cancer at a 
37% higher rate than Caucasian men while Hispanics have an almost 50% lower 
incidence of lung cancer as compared to Caucasians, in part due to less smoking (ACS, 
2012).  Overall, African Americans have a higher cancer incidence rate than other racial 
and ethnic groups and a mortality rate that is approximately 30% higher than Caucasians 
(ACS, 2013; ALA, 2010; Office of Minority Health, 2013, SEER, n.d.).  The incidence of 
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patients diagnosed with advanced stage IIIB lung cancer is 17.6% and 40% with 
metastatic stage IV disease (National Cancer Institute [NCI], 2011).  
The mortality rates for most major cancers such as colon, breast, and prostate 
have been decreasing; however, the lung cancer mortality rate, though it has decreased 
due individuals quitting smoking, has not decreased as fast over the past decade (Lung 
Cancer Alliance, 2012).  The 2013 Cancer Facts and Figures statistics show that the lung 
cancer death rate for African Americans has declined faster than Caucasians (2.4% vs. 
1.9%) due to more African Americans quitting smoking, but there still remain differences 
in lung cancer mortality between African American, Hispanic, and Caucasian populations 
(ACS, 2013).  The differences in lung cancer mortality between Caucasians and African 
Americans are the result of a number of factors, including differences in access to care, 
quality of care, bias in treatment, stereotyping, and socioeconomic status (SES; Clark, 
2009).  Lower SES is frequently associated with lower health literacy and the ability to 
understand healthcare information (ASCO, 2014).  In fact, an analysis of the data reveals 
that racial disparity has not decreased in the10 years from 1992 to 2002 (Gross, Smith, 
Wolf, & Andersen, 2008).  This fact has been confirmed by other studies (Kaiser Family 
Foundation, 2012). 
Much of the research contributing to the understanding and elimination of 
disparities has focused primarily on the best-known factors associated with the 
determinants of health such as race/ethnicity and SES (Berkowitz & McCubbin, 2005).  
Healthcare disparities related to societal marginalization, patient distrust of the medical 
community, and institutional discrimination are known to be present (Anderson, 2014).  
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Patients who are marginalized have been shown to experience delays in the diagnosis and 
treatment of their cancer and are less likely to receive recommended treatment options 
leading to decreased survival (Anderson, 2014).  Additional research in these areas of 
health care processes and quality of treatment and care may contribute to our 
understanding and help eliminate the disparities experienced by many racial/ethnic 
minorities (Gross et al., 2008).  The Institute of Medicine (IOM) highlighted the need to 
avoid ineffective care and to increase the use of practices with proven evidence 
(Smedley, 2003).  In an effort to reach the IOM goal, President Clinton initiated the 
Racial and Ethnic Health Disparities Initiative and set the goal of eliminating racial 
disparities by 2010 (Health and Human Services, 1998).  Because the United States did 
not meet the goal of eliminating the multifaceted problem of health care disparity by 
2010, solving this problem remains a focus for the United States.  While the United 
States is known to have one of the best health systems, evidence shows there is 
inconsistent care given to cancer patients and that African Americans are less likely than 
Caucasians to receive stage appropriate treatment for lung cancer (American Society of 
Clinical Oncology (ASCO), 2013; Betancourt & Renfrew, 2011; IOM, 2013; Shugarman 
et al., 2009).  
One strategy to aid in reducing the disparities in cancer treatment between 
racial/ethnic groups is to use evidence-based clinical practice guidelines that are disease 
specific.  The National Comprehensive Cancer Network (NCCN) clinical practice 
guidelines are the most widely accepted and used cancer guidelines and have been shown 
to improve the quality of care in cancer patients by providing the physician with the best 
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clinical evidence available from randomized clinical trials for treating a cancer (ASCO, 
2013; NCCN, 2014; Smith, 2000).  The NCCN clinical practice guidelines were 
developed by experts from a number of major cancer centers in the United States using 
an unbiased process for evaluating clinical trial data and the clinical research literature in 
an effort to aid in the treatment decision-making process.  The NCCN clinical practice 
guidelines are classified into categories (Category 1, 2a, 2b, and 3) by the strength and 
consistency of the evidence and the consensus panel agreement to the recommended 
guidelines.  Clinical practice guidelines and standards of care change over time 
depending on the data released from clinical trials.  The current recommended guideline 
for stage IIIB non-small cell lung cancer (NSCLC) is concurrent chemoradiation and for 
first-line stage IV NSCLC is a two-drug combination of a platinum drug (either 
carboplatin or cisplatin) plus another drug such as docetaxel, gemcitabine, pemetrexed, 
paclitaxel, or vinorelbine.  The addition of a biologic drug such as bevacizumab is 
indicated for patients with nonsquamous NSCLC.  Following the recommended clinical 
practice guidelines provides the scientific basis for medical treatments, providing for 
consistent practices among physicians, increasing quality care while allowing for fewer 
treatment differences between patients, increasing efficiency, and lower costs.  Overall, 
the guidelines provide a roadmap for treatment but are not mandatory as physicians are 
able to make certain clinical decisions based on each patient’s overall medical condition.  
As the cost of the new therapeutic agents adds to the overall cost of treatment, it is key 
that the clinical practice guidelines are incorporated into treatment decisions because 
clinical practice guidelines are used for reimbursement by payers and for advocating for 
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policies to ensure access to cancer care.  The relationship between the provider and the 
patient may also be improved if there is a discussion about clinical practice guidelines 
and involving the patient in their own care allowing for improved treatment compliance.  
The NCCN clinical practice guidelines are available for 97% of cancers and can be 
applied to approximately 97% of the population in the U.S. (NCCN, 2014).  However, 
having clinical practice guidelines available does not ensure that they will be used 
because the guidelines are not mandatory (Mok, 2014). 
  The goal for this research was to retrospectively evaluate the specific cancer 
treatment of elderly African Americans, Caucasians, and Hispanics with advanced stage 
IIIB or stage IV metastatic NSCLC using a national database from the NCI to evaluate 
treatment according to the NCCN clinical practice guidelines.  The results from lung 
cancer research and health outcomes research in the early stages of NSCLC demonstrated 
differences in the rate of surgery in African Americans and Caucasians.  However, there 
is limited research on lung cancer treatment in Hispanics, as well as on lung cancer 
treatment patterns in the advanced stage of the disease comparing Caucasians, African 
Americans, and Hispanics (Shavers & Brown, 2002).  There is also little to no data on the 
use and effect of clinical practice guidelines in lung cancer across racial/ethnic groups.  
Therefore, the focus of this study was to evaluate the treatment of elderly Hispanic 
patients diagnosed with advanced/metastatic NSCLC compared to African Americans 




 This study contributed to the body of research in lung cancer disparity as it related 
to the treatment of different ethnic groups according to the recommended treatment 
guidelines established by NCCN.  If patients are not treated according to the 
recommended lung cancer guidelines for stage of disease, treatment differences may be 
exaggerated.  While it was difficult to determine the reason treatment was not provided 
according to the clinical treatment guidelines, this research provided an understanding of 
the treatment in NSCLC in African Americans, Hispanics, and Caucasians and provided 
insight into whether physicians may be contributing to disparities by potentially not 
following the clinical practice guidelines.  Having an understanding of cancer treatment 
patterns between racial/ethnic groups may allow the healthcare community to better 
understand the potential causes for the disparities and identify strategies for eliminating 
the disparity.  Social change can be achieved through improving the understanding of 
racial disparities, increasing awareness, and educating healthcare providers around 
racial/ethnic differences and cultural sensitivity toward these groups. 
This chapter provides the background on health disparity in lung cancer between 
African Americans, Hispanics, and Caucasians with regards to the first line treatment of 
advanced NSCLC.  I will introduce the problem statement, the purpose of the study with 
research questions and hypotheses, definitions of terms, and the limitations to a 
retrospective study using a large population database.  Clinical practice guidelines 
provide healthcare providers with a resource for more consistent treatment across 
racial/ethnic groups and ensure that the most current research discoveries are 
incorporated into patient treatments.  However, there tends to be variation in the use of 
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these guidelines across disease entities.  Therefore this study helped determine the extent 
to which clinical practice guidelines were used in the first line treatment of 
advanced/metastatic NSCLC in the elderly and address the needs for additional research. 
Background 
Lung cancer is a devastating disease and its incidence is expected to increase 
worldwide over the next decade (ACS, 2014).  Currently there are 1.6 million deaths 
annually worldwide due to lung cancer and the WHO predicts a 70% increase in cancer 
by 2030 (WHO, 2014).  Eighty percent of lung cancers are diagnosed in current and 
former smokers, in addition to individuals exposed to second hand smoke and 
environmental pollutants, which also increase the risk of developing lung cancer.  
Smoking is the leading cause of preventable cancer mortality in the United States and 
worldwide (CDC, 2008).  Approximately 56% of lung cancers are diagnosed once they 
have spread to other parts of the body (Lung Cancer Alliance, 2013).  The overall 5-year 
survival rate for lung cancer is approximately 16%, which is less than the 5-year survival 
for the other major cancers in the United States, including breast, colon, or prostate 
cancer (Lung Cancer Alliance, 2013; SEER, n.d.).  With regards to lung cancer mortality 
and general cancer mortality, lung cancer represents 27% of all cancer deaths in the 
United States (SEER, n.d.).  African Americans have the highest mortality rates from 
cancer, including lung cancer.  The cancer mortality rate for African American men 
between 2003 and 2007 was 296/100,000 compared to 225/100,000 for Caucasians 
(ASCO, 2013).   
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Disparities in cancer mortality have been well documented in the medical and 
public health literature.  In 2002, the IOM published a report describing the disparities in 
healthcare between racial/ethnical groups and outlined multiple factors that contributed to 
the differences, including socioeconomic status, insurance status, access to healthcare, the 
healthcare provider, and the healthcare system, among other factors.  Even when 
controlling for socioeconomic status, insurance status, and access to healthcare, the 
research has shown that there has not been an improvement in cancer disparities; 
however, there has been a slow improvement in the quality of care for some cancer 
patients due to newer treatments (ASCO, 2013; Rust & Cooper, 2007).  But the greatest 
opportunity for improving disparities in healthcare exists in the healthcare system 
(Kilbourne, Switzer, Hyman, Crowley-Matoka, & Fine, 2006).  Multiple factors within 
the healthcare system contribute to cancer disparity, including patient delays in obtaining 
care, physician delay in treatment, patient-physician interaction, lack of minority patient 
providers within the healthcare system, and the regulations, policies, and resources within 
the hospital, academic center, or clinic organization (Smedley, 2003).  
Since the publication of the IOM report on healthcare disparities, research has 
been dedicated to determining the reasons for the differences in healthcare treatment and 
outcomes.  Several definitions of disparities are used in the literature. The IOM defined 
disparities as “the difference in healthcare services received by different racial/ethnic 
groups that is not due to clinical need/appropriateness or preference by the individual” 
(Smedley et al., 2003.  Freeman and Chu (2005) described the causes for disparities in 
cancer care and outcomes as culture, poverty, and social injustice.  Cultural barriers occur 
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when there are certain beliefs about cancer and treatment and when there is a lack of 
information and understanding about cancer.  To overcome some of the barriers of 
culture, poverty, and social injustice Freeman and Chu reference the use of patient 
navigators. Freeman and Chu also found that the healthcare provider might be 
contributing to the disparities between patients because, when healthcare providers treat 
patients, there is an inconsistency between what the provider knows and what the 
provider provides to the patient.  Betancourt and Renfrew (2011) and Kilbourne et al. 
(2006) found that poor communication between the patient and the healthcare provider, 
stereotyping/bias, the clinical decision process, and patient mistrust were causes for the 
differences in healthcare.  By applying equal treatment to all patients treatment 
inequalities can be reduced.  
One hypothesis for the causes of the disparities between racial/ethnic groups 
comes from the social cognitive theory (SCT).  The SCT has been used to understand 
physician actions, physician attitudes, and unconscious thinking process.  Research has 
found that stereotyping by healthcare providers contributed to the differences in treatment 
between racial/ethnic groups (Burgess, 2010; Burgess et al., 2004).  Physicians are taught 
to eliminate their personal judgment about patients; however, research has found that 
physicians unconsciously assign patients to a category, which influences treatment 
decisions, leading to differences in treatment patterns (Burgess et al., 2004; Kilbourne et 




The incidence and burden of lung cancer varies considerably according to the 
demographic characteristics of patients, especially age, gender, and race/ethnicity.  While 
Hispanic men and women have one of the lowest incidences of lung cancer, African 
American men have the highest incidence of lung cancer with 95.8 cases per 100,000 
persons per year, compared to Caucasian men (74.5 cases/100,000 persons per year) and 
Hispanic men (40.6 cases/100,000 persons per year; ACS, 2012; SEER, n.d.).  Hispanic 
women have the lowest incidence of lung cancer with 26.3 cases per 100,000 persons per 
year as compared to African American women 38.0/100,000 and Caucasian women 
40.0/100,000 (ACS, 2013; SEER, n.d.).  Overall, five-year survival rates for African 
Americans are also lower than those observed in Caucasians or Hispanics, 12.4% as 
compared to 15.9% for Caucasian and 14.4% for Hispanics (ACS, 2012; ALA, 2010).  
Despite low incidence rates, lung cancer is the leading cause of death among Hispanic 
men and the second leading cause of cancer death among Hispanic women (ACS, 2012).  
While there have been advances in the treatment of lung cancer and a decrease in the 
incidence and mortality rates, the decreased rates have not been seen across all 
races/ethnicities with African Americans still having a disproportionate burden of cancer 
in the United States (Betancourt & Renfrow, 2011; Freeman & Chu, 2005; National 
Cancer Institute, 2008; Office of Minority Health, 2013).  Patients with metastatic stage 
IV NSCLC that has spread outside of the lungs are usually treated with chemotherapy to 
control their disease (NCI, 2013; NCCN, 2014).  The treatment of lung cancer in the 
context of the clinical trial setting is well documented in the literature; however, there are 
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few data on how patients with advanced stage IIIB/metastatic stage IV lung cancer are 
treated in the real world outside of the clinical trial setting (Reilly & Evans, 2006).  While 
the NCCN clinical practice guidelines for NSCLC have been in place since 1996 (NCCN, 
2014), it is not known if the treatment outside of a clinical trial in the advanced/metastatic 
first-line setting is equal across all demographic and clinical subgroups with similar stage 
of NSCLC or to what extent the NCCN lung cancer clinical practice guidelines are 
applied across different groups of patients.   
In the clinical trial setting, patient inclusion/exclusion are generally well defined 
and well controlled for comorbidities and concomitant medications; however, these 
variables are not well controlled in the real world, which illustrates the difference 
between treatment in a clinical trial and real world treatment.  It remains unclear if 
treatment and outcome disparities are due to the individual patient or to institutional 
factors.  Therefore, the purpose of this study will be to fill this gap in the literature and 
evaluate how advanced stage NSCLC treatments compare across racial/ethnic groups 
(i.e., African Americans, Hispanics, and Caucasians) as stratified by stage of disease and 
histology according to the NCCN clinical practice guidelines while controlling for age 
and gender. 
  In this study, I evaluated the relationship between first-line treatment for 
advanced/metastatic NSCLC between African American, Hispanic, and Caucasian 
individuals age 65 years and older and patients characteristics such as age, gender, stage, 
and histology according to clinical practice guidelines.  As the Hispanic population in the 
United States increases, their inclusion in research efforts becomes more important.  I 
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evaluated lung cancer treatment according to established guidelines by race/ethnicity, 
stage of disease, histology, geographic location, and age in order to determine potential 
variation in treatment and identify ways to improve treatment outcomes.  The implication 
for positive social change from this research included an improved understanding of the 
treatment trends for first-line metastatic NSCLC, particularly in Hispanics, and a better 
understanding of the population at the highest risk of lung cancer mortality.  This 
understanding has implications for changing public policy and insurance reimbursement.  
This study was important to conduct, as it is well known that disparities in the early 
treatment of NSCLC exist; however, there are limited real-world data available regarding 
the treatment patterns. There is also limited real-word data across race/ethnicity regarding 
the treatment of patients in the later stages of lung cancer.  
Purpose of the Study 
 The purpose of this retrospective quantitative research study was to determine the 
relationship among Caucasian, African American, and Hispanic race/ethnicity, as 
stratified by histology (squamous vs. adenocarcinoma), and stage of disease (IIIB or IV) 
to the receipt of first-line treatment for NSCLC.  Within each of the four strata (stage IIIB 
disease adenocarcinoma or squamous cell carcinoma and stage IV disease 
adenocarcinoma or squamous cell carcinoma), I controlled for age and gender. Treatment 
according to the clinical practice guidelines was defined as the use of a recommended 
chemotherapy, radiation therapy, biologic agent, or combination of these therapies 
appropriate for the stage of disease and histology. 
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Research Questions and Hypotheses 
To better understand the treatment patterns of elderly African Americans and 
Hispanic patients relative to Caucasians with NSCLC, I explored the following research 
question and tested hypotheses to address the questions across the three ethnic groups.  
Each of the following hypotheses was tested within the respective stage and histology, 
creating a total of four strata.  The four strata were (a) stage IIIB adenocarcinoma; (b) 
stage IIIB squamous cell carcinoma; (c) stage IV adenocarcinoma; (d) stage IV squamous 
cell carcinoma. 
Research Question: What is the likelihood of Caucasian, African American, and 
Hispanic patients with NCSLC being equally treated according to the NCCN clinical 
practice guidelines within stage and histology strata after controlling for age and gender?   
Null Hypothesis (H0): Caucasian and African American patients with NSCLC are 
equally likely to be treated according to the NCCN clinical practice guidelines within 
stage and histology strata, after controlling for age and gender. 
Alternative Hypothesis (H1): Caucasian and African American patients with 
NSCLC are not equally likely to be treated according to the NCCN clinical practice 
guidelines within stage and histology strata after controlling for age and gender. 
2.   What is the likelihood of Caucasian and Hispanic patients with NSCLC being 
equally treated according to the NCCN practice guidelines within stage and histology 
strata after controlling for age and gender? 
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Null Hypothesis (H2o):  Caucasian and Hispanic patients with NSCLC are equally 
likely to be treated according to the NCCN practice guidelines within stage and histology 
strata after controlling for age and gender. 
Alternative Hypothesis (H21):  Caucasian and Hispanic patients with NSCLC are 
not equally likely to be treated according to the NCCN practice guidelines within stage 
and histology strata after controlling for age and gender.    
3.  What is the likelihood of Hispanic and African American patients with 
NSCLC being equally treated according to the NCCN practice guidelines within stage 
and histology strata after controlling for age and gender? 
Null Hypothesis (H3o):  Hispanic and African American patients with NSCLC are 
equally likely to be treated according to the NCCN practice guidelines within stage and 
histology strata after controlling for age and gender. 
Alternative Hypothesis (H31):  Hispanic and African American patients with 
NSCLC are not equally likely to be treated according to the NCCN practice guidelines 
within stage and histology strata after controlling for age and gender.    
Theoretical Framework 
Many factors influence racial/ethnic disparities, and as such, researchers have 
used numerous theories to evaluate the differences, with no one overarching theory being 
used to describe the healthcare differences seen among different groups.  The theory that 
served as the foundation for this study in the use of clinical practice guidelines in NSCLC 
between racial/ethnic groups was the SCT by Bandera.  SCT posits that one’s behavior is 
based on environmental factors such as educational training, colleagues, family and 
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friends, and observation, as well as personal factors such as cognitive and emotional 
factors that all interact with each other (Burgess et al., 2004).  SCT has two components 
based on past experiences, one is cognition, and the other is motivation.  These 
components have been used in previous cancer research to evaluate how individuals 
acquire their learning and how one’s past learning and past behaviors influence treatment 
patterns.  SCT has been used to determine an individual’s self-efficacy in treating 
individuals of difference racial/ethnic backgrounds (Burgess et al., 2004).   
SCT has been used to consider one’s thought processes, one’s judgment, and 
one’s social influences in understanding racial/ethnic interactions in healthcare decisions.  
If a healthcare provider believes that a patient or caregiver is less likely to adhere to a 
recommended treatment or lacks support from family or friends, the healthcare provider 
may not prescribe the therapy but instead prescribe a more appropriate therapy (van Ryn 
& Fu, 2003).  Burgess et al. (2010) state that, when physicians interact with racial/ethnic 
minorities, the physician may experience anxiety, which in turn affects their ability to 
make treatment decisions.  There is also some evidence to suggest that the health system 
contributes to disparity and that interventions to eliminate disparities can be improved by 
providing treatment decisions that are less demanding and less mentally intense (van Ryn 
& Fu, 2003).  The factors that contribute to healthcare disparity include the patient, the 
physician, the patient-physician interaction, third party payers, referral patterns of 
physicians, and the guidelines within the hospital, academic center, or clinic organization 
(Kilbourne et al., 2006, Figure 1).  Institutional clinical practice guidelines may or may 
not be in place that physicians follow when treating their patients (Yorio, Yan, Xie, & 
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Gerber, 2012).  Clinical treatment guidelines provide the physician with the tools to treat 
cancer patients equally according to the best available evidence-based research and make 




Figure 1. A Conceptual Framework Describing Healthcare Disparities.  From 
“Advancing health disparities research within the health care system: A conceptual 
framework,” by A. M. Kilbourne et al., 2006, American Journal of Public Health, 96, p. 
2116.  Reprinted with Permission. 
Nature of the Study 
This study was a retrospective quantitative analysis of the treatment of elderly 
African Americans, Hispanics, and Caucasians with advanced stage IIIB and metastatic 
stage IV NSCLC using a secondary data source from the NCI (described below).  In this 
study, I tested whether there are differences in the chemotherapy, radiation therapy, or 
biologic therapy administered in the first line treatment of African American and 
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Hispanic patients with NSCLC as compared to Caucasians.  All patients had stage 
IIIB/IV NSCLC and comparable stage of disease.  I identified and stratified patients by 
stage (IIIB or IV) and lung cancer histology (squamous or nonsquamous histology). Age 
and gender were controlled for using multivariable analyses.  The criterion variable was 
cancer treatment according to the NCCN clinical practice guidelines and the predictor 
variables were age, gender, and race/ethnicity (African American, Hispanic, or 
Caucasian).  Analyses were performed within stage and histology strata given the 
differences in treatment guidelines across these groups.  All patients were Medicare 
recipients and had comparable insurance coverage.  The study was based on practice 
guidelines for advanced/metastatic NSCLC using the 2008 NCCN practice guidelines for 
patients diagnosed with NSCLC between 1998 and 2008 and the 2010 practice guidelines 
for patients diagnosed from 2008 and 2010. The outcomes were reported as whether the 
treatment given followed the recommended NCCN clinical practice guidelines according 
to stage and histology. 
Data Source 
 The NCI initiated the SEER program in 1972.  SEER collects data from 
population-based cancer registries in the United States based on cancer incidence and 
prevalence, geographic location, cancer survival rates, and cancer mortality rates 
representing 28% of the U.S. population from 18 U.S. cancer registries (SEER, 2013c; 
Warren et al., 2002).  The SEER database contains 250,045 patients with lung cancer 
diagnosed from 1991 to 2009 (SEER, n.d.).  In 1991, the NCI and the Centers for 
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Medicare and Medicaid Services (CMS) began linking the SEER registry data with 
Medicare claims data. 
 The lung cancer patients for this study were abstracted from the NCI SEER linked 
Medicare database and included cancer cases reported in SEER from 1998-2011 and 
Medicare claims from 1991-2010.  I selected the SEER database because it is the 
standard cancer research tool for healthcare researchers who are studying health patterns 
and outcomes (Abel, 2011; NCI, 2013).  Furthermore, the SEER database contains a high 
racial/ethnic mix and the database population has a similar education and socioeconomic 
mix to the general population (Abel, 2011).  SEER data are available on age, gender, 
ethnicity, and year of cancer diagnosis for 26% of African Americans, 38% of Hispanics 
and 25% Caucasians (SEER, 2013c).  Hispanic ethnicity in SEER is determined through 
a Hispanic surname algorithm from the North American Association of Central Cancer 
Registries Hispanic Identification Algorithm that was developed for enhanced sensitivity 
compared to what was recorded in the Medicare database (SEER, n. d.).  The Medicare 
database contains claims information on healthcare procedures and utilization in 
individuals 65 years of age and older with data available for the years 1991-2010.  The 
SEER and Medicare linked databases were used to identify specific chemotherapy agents 
to treat lung cancer and to identify patterns of lung cancer care according to clinical 
practice guidelines.  Additional focus was on newer agents approved from 1998-2010 as 
these drugs are widely used by oncologists and are part of the standard of care for treating 
NSCLC.  Claims data were evaluated starting in 1998, when several chemotherapeutic 
agents were approved for lung cancer.  The Food and Drug Administration (FDA) 
19 
 
approved paclitaxel (Taxol) for use in NSCLC in 1998 and docetaxel (Taxotere) was 
approved in 1999 for NSCLC as a single agent.  The FDA approved pemetrexed (Alimta) 
for NSCLC in 2004 and bevacizumab (Avastin) was FDA approved in 2006 for 
unresectable adenocarcinoma NSCLC.  Erlotinib (Tarceva), an oral chemotherapeutic 
agent was FDA approved for the first-line treatment of advanced or metastatic NSCLC in 
2013.  Only chemotherapy administered claims data were evaluated to determine how 
these new biologic/targeted agents were used in elderly Caucasians, African Americans, 
and Hispanics diagnosed with NSCLC. 
Definition of Terms 
 An understanding of the terms and acronyms used throughout the lung cancer and 
disparities literature are important for understanding this research.  Following are the 
definitions of the acronyms and terms used in this research. 
 African American: An individual who is descended from any of the Black 
populations in Africa.  Also includes individuals from Haiti and Jamaica (U.S. Census 
Bureau, 2010). 
 Caucasian: An individual of White race and has European, Middle Eastern or 
North African origins (U.S. Census Bureau, 2010).  
Clinical practice guidelines: Treatment recommendations based on a methodical 
review of clinical evidence to optimize patient care (Institute of Medicine, 2011). 
 Disparity: Increase in the incidence, prevalence, burden of disease, and death 
from disease in a population as compared to the general population (NCI, 2013). 
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First-line therapy: The first treatment recommended for a disease and is usually 
the standard treatment based on clinical guidelines (NCI, n.d.). 
Hispanic: A person of Mexican, Puerto Rican, Cuban, Central, or South 
American, or other Spanish culture (U.S. Census Bureau, 2010). 
Metastatic: Cancer that has spread to another part of the body, outside of its 
original site (NCI, 2013). 
National Comprehensive Cancer Network (NCCN): A group of 23 cancer centers 
in the United States that develop clinical practice guidelines that will improve the quality 
and effectiveness of cancer care for patients (NCCN, 2014). 
Non-small cell lung cancer (NSCLC): Type of cancer that originates in the 
bronchus of the lung and is defined by the appearance of the cells (ACS, 2014). 
Overall survival rate: The percentage of people who are still alive after they are 
diagnosed with cancer or started treatment for a disease (NCI, n. d.). 
Randomized clinical trial: A study in which the participants are assigned by 
chance to separate groups that compare different treatments. Neither the researchers nor 
the participants can choose the group (American Association for Cancer Research 
[AACR], 2011). 
Stage of disease: The amount of cancer and whether the cancer has spread from 
the original site of diagnosis to another part of the body. The stages of cancer differ for 
each cancer type and with the staging system (AACR, 2011). 
Standard of care: The currently accepted and widely used treatment for a 
particular cancer based on previous clinical research (AACR, 2011). 
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Social cognitive theory (SCT): A model that states individuals learn and gain 
knowledge based on experience, motivation, observing others, and interactions with 
others (Pajares, 2002). 
Self-efficacy: An individual’s capability to succeed in a particular situation 
(Bandura, 1977). 
Targeted agents: A treatment using drugs or other agents that attack specific 
cancer cells while limiting the effect on normal cells (AACR, 2011).  
Tumor board: A group of physicians and healthcare providers from different 
cancer specialties who discuss a patient medical case and options for treatment (Scher, 
2012). 
Assumptions 
 One of several assumptions made for this study was that the study data were 
representative of the lung cancer population in the United States over 65 years of age.  It 
was also assumed that differences in treatment outcomes would be due to noncancer 
health and co-morbidities.  It was further assumed that the stage of lung cancer and 
histology would be sufficient to determine appropriate lung cancer care.  It was also 
assumed the data from the SEER-Medicare database were complete and accurate, and 
that racial/ethnic classifications were accurate. 
Scope and Delimitations 
The strengths of this study are that this is a large retrospective population-based 
study using the SEER database that collects data representing 28% of the U.S. 
population.  The combined SEER database and the Medicare database provided for a 
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more complete analysis of the data and allowed for identifying chemotherapy treatments 
as compared to using the SEER database alone.  SEER collects data from hospitals, 
physician offices, clinics, nursing homes, and radiation facilities and is able to capture 
approximately 99% of all cancers (NCI, 2012). 
This was a retrospective study and was limited as to why a specific treatment was 
not given.  It would be difficult to determine whether the treatment was not given because 
of patient refusal, whether the physician did not offer the treatment, or because comorbid 
conditions existed.  Because the population studied was aged 65 years and older with 
Medicare the results cannot be generalized to the general population.  The use of a 
Medicare database limits this research to only patients with Medicare Part A and Part B 
and results from this study may not apply to commercially insured patients or patients 
treated in a Veterans Affairs facility.  Also, because this study was an evaluation of 
patients with advanced/metastatic NSCLC, the results cannot be generalized to patients 
with earlier stage disease.  The SEER-Medicare database does not contain data on the 
patient performance status, one of the indicators oncologists use when making treatment 
decisions.  SEER represents approximately 28% of the U.S. population; therefore, local 
treatment differences may not be reflected in this study.  Another limitation may be the 
misclassification of a patient’s ethnicity, particularly Hispanic ethnicity, in cancer 
registries and in the SEER database.  Accounting for missing variables is a limitation to 




 Participation was delimited to patients with a diagnosis of advanced stage IIIB or 
stage IV metastatic NSCLC who are Caucasian, Hispanic, or African American; are age 
65 or older; and are enrolled in Medicare Part A and Medicare part B insurance upon 
being diagnosed with NSCLC.  The Medicare database does not include patients with 
Medicare insurance Part C (HMO/PPO); therefore, these patients were not included in the 
study.  As well, patients who may have been diagnosed with another cancer prior to lung 
cancer, except non-melanoma skin cancer were excluded from this study.  Patients with 
stage I-IIIA NSCLC at diagnosis and patients with histology other than adenocarcinoma 
or squamous cell carcinoma were also excluded from study because disparities in patients 
with early stage disease had been fairly well studied.  
Significance of the Study 
Previous research has shown that when patients have similar insurance status, 
there are differences in care received between racial/ethnic individuals.  Clinical practice 
guidelines in oncology have been developed for most all tumor types and are available to 
all healthcare professionals.  Following clinical practice guidelines allows for more 
consistent patient care with less risk of inappropriate care and increased costs (Field & 
Lohr, 1992).  This study helps advance the knowledge of cancer disparities by focusing 
on the healthcare system as a factor contributing to the gap in cancer care.  While it is 
well known that differences in the receipt of health care exist among minority groups due 
to lack of insurance or access to care, this research was focused on understanding other 
factors that contribute to the gap in health care and outcomes by evaluating the use of 
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clinical practice guidelines in patients with advanced/metastatic NSCLC with similar 
insurance status.  By focusing on factors contributing to the gaps in patient care from the 
health system, additional insight may be gained to explain the disparities seen and 
provide the potential for additional prospective research evaluating the health care system 
as a factor contributing to differences in cancer care.  
Summary 
There are challenges to reducing the gaps in health care and outcomes among 
racial/ethnic groups.  Eliminating these disparities is a goal of most public health 
professionals and is also one of the goals for Healthy People 2020 (Healthy People, 
2010).  
 Much of the research in health disparities has focused on social determinant 
factors with less emphasis on the health care system as a contributor to the disparities in 
care.  Even when SES, insurance status, access to care, and stage of disease are equal, 
gaps in the health outcomes remain.  Racial/ethnic minorities receive lower quality care 
and have lower health outcomes.  Research from Burgess (2002, 2010) and van Ryn 
(2002) suggested that physician behaviors and bias may contribute to disparities.  
Researchers have also documented discordant relationships between physicians and 
patients. Physicians’ unconscious stereotypes and biases may be affecting self-efficacy, 
communication with patients, and adherence to recommended practice guidelines 
(Burgess et al., 2010).  Improving quality of care may improve the communication 
between the patient and physician and facilitate a mutually shared treatment decision-
making process, where the physician is not solely held responsible for the treatment 
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decisions.  Improving patient care through evidence-based medicine and reducing costs 
with greater efficiency may be possible.  Clinical practice guidelines provide evidence-
based recommendations appropriate for stage of disease and can potentially increase 
physician self-efficacy when interacting with racial/ethnic minorities. 
In Chapter 2, I will outline the study framework described in Chapter 1 in further 
detail by providing a thorough review of literature on relevant concepts and theories and 
literature related to the research questions, hypotheses, the problem statement, and the 
study objective.  In addition, I will provide a historical perspective of lung cancer 
treatment in Chapter 2.  Chapter 3 will include a description of the nature and design of 
the study, the patient population with justification for the sample size, the research 




Chapter 2: Literature Review 
Introduction 
Lung cancer is a major health problem in the United States.  In 2012, there were 
approximately 226, 000 new cases of lung cancer diagnosed with approximately 112,000 
deaths due to the disease (NCCN, 2014).  African Americans have the highest incidence 
rate of lung cancer at 75/100,000 as compared to Caucasians at 64/100,000, and 
Hispanics have the lowest incidence of lung cancer at 32/100,000 (ALA, 2010).  There 
are numerous studies to confirm the association between cigarette smoking and lung 
cancer with the majority of lung cancers that develop in smokers being preventable.  
Lung cancer is usually diagnosed in the sixth or seventh decade of life and in the 
advanced stage of disease when the prognosis is poor and when the disease is rarely 
curable (ALA, 2010).  NSCLC and small cell lung cancer (SCLC) represent the two 
major types of lung cancer with non-small cell lung cancer representing 85% of all lung 
cancer cases (ALA, 2010).  Overall, most minorities have higher incidence rates, higher 
mortality rates, and lower 5-year survival rates after being diagnosed with cancer as 
compared to Caucasians (ACS, 2013; ASCO, 2013).  Despite treatment with 
chemotherapy, radiation, and newer targeted agents, lung cancer still has a higher 
mortality rate as compared to other cancers (ALA, 2013).  According to the ACS (2009), 
as the technologies and therapies to treat cancer improves, racial/ethnic disparities may 
also increase. 
Major advances in the treatment of lung cancer have occurred in the past 30 years, 
yet not all individuals share equally in receiving cancer care (Freeman & Chu, 2005; 
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Lillie-Blanton et al., 2008).  Cancer care is complex.  There are multiple factors that 
directly impact the patient and that contribute to the disparities in cancer care seen 
between African Americans, Hispanics, and Caucasians.  These factors include lack of 
education, lack of access to care, environmental factors, racism, the type of health 
insurance, and the overall healthcare system (Betancourt et al., 2011).  Differences in 
referral patterns to a cancer specialist and differences in the level of insurance coverage 
may determine the type of treatment given.  Patients with a lower level of benefit may not 
receive the same treatment as a patient with a higher level of the same insurance benefit 
(Slatore, Au, & Gould, 2010).  These differences may also be due to the type of facility 
where treatment is received and constraints within the healthcare facility such as 
reimbursement and available resources (Kilbourne et al., 2006).  The IOM published a 
landmark paper entitled “Unequal Treatment: Confronting Racial and Ethnic disparities 
in Healthcare” that reported on the disparities seen in healthcare and on the factors that 
contributed to the disparities (Smedley et al., 2003).  Minorities tended to receive poorer 
quality of care than nonminorities even when there was equal insurance and income level 
(American College of Physicians, 2010; Betancourt & Renfrew, 2011; Clark, 2009; 
Smedley et al., 2003).  Factors contributing to the disparities included poor 
communication between the patient and the healthcare provider, stereotyping/bias by the 
healthcare provider, and historic treatment practices that may have caused African 
American patients to mistrust the healthcare provider and the healthcare system 
(Betancourt & Renfrew, 2011; Meyers, 2007; Smedley et al., 2003).  Differences in care 
were noted between teaching and nonteaching hospitals, referrals to specialty physicians, 
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and the availability of translators to aid in communicating with the healthcare provider. 
Data from the literature also show that other factors contributing to the increased 
mortality and disparities in lung cancer are stage of disease at diagnosis and the effective 
treatment of the disease (Li et al., 2011).  In addition, the IOM noted that healthcare 
providers might contribute to the differences in care through their own beliefs about race 
and subconsciously decide how to treat the patient (Smedley et al., 2003).  In a follow-up 
report, Clark (2009) noted that little to no progress was made in providing access and 
quality care toward eliminating healthcare disparities since the 2003 IOM report.  These 
themes from the IOM paper have been documented over the years.  Forty years after the 
first healthcare disparities paper was published, suboptimal cancer treatment for many 
patients still exists (Lillie-Blanton et al., 2008). 
In an effort to reduce the lung cancer death rate and improve the treatment of 
cancer patients, Healthy People 2020, a national initiative from the U.S. Department of 
Health and Human Services, set the cancer goals of reducing the overall cancer death rate 
and reducing the lung cancer death rate in individuals by 2020 (Healthy People 2020, 
2013).  However, if healthcare disparities are to be eliminated, the cause of the disparities 
must be understood.  Therefore, the purpose of this study was to conduct a retrospective 
evaluation of patients with advanced NSCLC to determine if treatment differences exist 
in the first-line setting of NSCSL between Caucasians, Hispanics, and African 
Americans.  
In this chapter, I outlined the current treatment standards for lung cancer, the 
current status around the use of clinical treatment guidelines in lung cancer, and how the 
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guidelines currently affect outcomes.  The theoretical foundations behind healthcare 
disparities were described using the SCT and the cancer disparities model.  This paper 
contributes to the current body of literature in the area of healthcare disparities in African 
Americans, Hispanics, and Caucasians. 
Literature Search Strategy  
The databases that I accessed to search for information on treatment guidelines in 
lung cancer in racial/ethnic minorities included PubMed, OVID, Medline, Scopus, and 
Google Scholar.  The terms I used to search for the most current peer-reviewed articles 
include NSCLC, non-small cell lung cancer, lung cancer, disparities, health care 
disparities, practice guidelines, insurance, clinical treatment guidelines, Hispanic, race, 
ethnicity, and quality of care.  Articles were limited to studies in the United States, 
published in English, with full-text available, that described racial/ethnic treatment 
patterns and disparities in lung cancer.  Articles were delimited to the years 2000 to 2013 
in order to capture the most current treatment practices in lung cancer.  I also researched 
the reference lists of identified articles for additional relevant papers.  Papers published 
prior to 2000 were included in order to capture several landmark papers that initially 
identified healthcare disparities in the United States and to capture background 
information around the theoretical foundations of healthcare disparities.  Articles 
describing healthcare disparities in advanced lung cancer patients were limited as most 
research describing disparities in NSCLC were conducted in early stage patients where 
the comparisons were primarily between African Americans and Caucasians.  Limited 
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data were found describing healthcare disparities in Hispanics with lung cancer and 
advanced disease. 
Theoretical Foundation 
The SCT by Bandura (1977) and the cancer disparities model by Freeman and 
Chu (2005) serve as the framework for this investigation.  The SCT originated from the 
field of psychiatry to describe learning behaviors and was later expanded by Bandura to 
include human behavior (Pajares, 2007).  The SCT describes the influence of three 
factors on behavior: environmental, behavioral, and personal.  The ability to change one’s 
thoughts and behaviors are dependent upon one’s perceptions, goals, and willingness to 
change (Smith, 2000). As such, the SCT has been applied to understand behaviors in 
stressful situations, problem-solving situations, and outcomes and expectations (Pajares, 
2002).    
One of the key factors of the SCT is self-efficacy, which was first introduced by 
Bandura (2005) (1977).  Self-efficacy provides for the modeling of behaviors and is 
obtained by observing the actions of others and from one’s own experiences (Pajares, 
2002).  According to the SCT, individuals have control over their thoughts while 
behaviors are influenced by one’s beliefs and capabilities (Pajares, 2002).  The use of 
social cognitive models has shown that prejudice and stereotyping by healthcare 
providers is a normal phenomenon.  Individuals have the ability to control their actions, 
beliefs, motivation, and control outcomes based on Bandura’s self-efficacy model.  This 
model can be applied to the confidence physicians have in their ability to treat different 
racial/ethnic patients, follow clinical guidelines, and treat NSCLC (Burgess et al., 2007).  
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Physicians who do not have positive interactions with racial/ethnic minority patients or 
are not confident in their ability to treat these patients may not communicate well with 
them or feel comfortable treating them.  This model can be applied to the confidence 
physicians have in their ability to treat different racial/ethnic patients, follow clinical 
guidelines, and treat NSCL.  As well, the patient may sense that the physician is 
uncomfortable and in turn may not trust the physicians’ judgment or follow the 
recommended therapy (Dans et al., 2007).  There is also evidence that individuals of 
different races/ethnicities process information differently and this difference affects 
behaviors and compliance to treatment (Van Ryn et al., 2003).  Even if the guidelines 
have the same effect in all races/ethnicities, physicians may make trade-offs when 
assessing the risks and benefits of the guidelines (Dans et al., 2007).  The physicians’ 
intention to use the guidelines and having the skills to treat the patient according to the 
guidelines are factors that can influence the use of the clinical guidelines (Michie et al., 
2005).  Physicians who do not believe in the clinical guidelines are less likely to follow 
the recommended clinical guidelines.  The use of clinical practice guidelines may also be 
a barrier if the healthcare provider lacks self-efficacy.  
Freeman and Chu’s (2005) disparity model describes three interrelated causes for 
the disparities seen in cancer care: (a) low SES; (b) culture; and (c) social injustice.  
Social injustice is defined as the bias associated with access to treatment, including 
geographic access, and the perceptions one has of racial/ethnic groups (Freeman & Chu, 
2005).  Within each of the three causes there are barriers that need to be overcome by the 
individual, by the healthcare provider, and by the healthcare system.  While research has 
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documented social determinants, insurance status, and access to care as contributors to 
racial/ethnic disparities, even when these factors are absent differences in care exist 
(Pienedo, 2011).  The ability of the patient to navigate the healthcare system has been 
shown to contribute to healthcare disparities (Freeman & Chu, 2005).  The relationship 
between the physician and the patient may be contributing to the disparities in care.  The 
effectiveness of communication, cultural awareness, and the patient’s level of trust in the 
physician are factors for a strong physician-patient relationship and are factors that 
contribute to the physicians’ treatment decisions.  However, research shows African 
American patients believe they have better relationships and treatment with their 
physician if they are of the same race/ethnicity (Saha et al., 2003).   
The conceptual framework for research gaps in the treatment of patients, 
according to race/ethnicity, can be reflected in the quality of care delivered and outcomes 
(Betancourt & Renfrew, 2011; Meyers, 2007).  The difference in quality cancer care 
ultimately affects the over or under utilization of resources and test, contributes to 
medical errors, and potentially increased medical costs.  While patient preferences may 
explain some of the differences in care, it only contributes a small part to cancer 
disparities.  Since the behaviors associated with healthcare treatment and outcomes are 
complex and involve multiple factors no one theory can be used to explain the treatment 
differences or the disparities seen in the care between racial/ethnic groups (Dressler et al., 




Historical and Current Perspective 
Over three decades ago the first paper that described the racial differences in 
cancer survival and mortality was published.  In this landmark paper entitled, “Alarming 
Increase in the Cancer Mortality in the U.S. Black Population (1950-1967),” Henschke et 
al (1973) described the differences in mortality rates between African Americans and 
Caucasians for a variety of cancers.  At the time, the biggest difference in the increased 
cancer mortality rate in African Americans was from lung cancer and this difference was 
thought to be due to environmental factors (Henschke et al, 1973).  With the increased 
number of African Americans who were being diagnosed with cancer and needing 
medical care, there was a burden on the healthcare system (Henschke et al., 1973).  This 
increase in the diagnosis of cancer and increase in cancer mortality in African Americans 
led to the initiation of cancer surveillance according to race and ethnicity that today now 
includes Caucasians, African Americans, and Hispanics among other races/ethnicities in 
the United States (Brawley, 2006).  To assess if there are differences in treatment across 
ethnicities/races this paper will determine how first line NSCLC treatments compare 
across racial/ethnic groups, specifically African Americans, Hispanics, and Caucasians 
and the likelihood of physicians treating according to the clinical practice guidelines. 
Prior to 1993 minorities and women were not routinely included in clinical trials 
and were therefore underrepresented in clinical research (Society for Women’s Health 
Research, 2011).  In 1987, the NIH developed a policy stating that minorities and women 
should be included in clinical trials. To ensure that these two groups were included in the 
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trials conducted through the NIH, the NIH Revitalization Act was passed in 1993 that 
mandated minorities and women be included in clinical trials and also required that the 
number of women enrolled in trials should be large enough to detect differences between 
the genders (National Institutes of Health, 2001).  In addition, gender and race were 
required to be analyzed to determine if there were differences in treatment (U.S. 
Department of Health and Human Services, 2005).  However, years’ later women and 
minorities are still underrepresented in most clinical trials (Intercultural Cancer Council, 
2011).   
Racial differences and health disparities between African Americans and 
Caucasians have been well documented over the years (Brawley, 2006; Freeman & Chu, 
2005; Lillie-Blanton et al., 2008; Shugarman et al., 2009; Smedley et al., 2003).  
According to the NCI, African Americans have the highest cancer incidence and 
mortality rates of any ethnic group (Howlander et al., 2013).  In fact, African American 
men have 1.4 times higher mortality rates from cancer as compared to Caucasian men 
(Shavers & Brown, 2002; Ward et al., 2004).  African Americans are also twice as likely 
as Hispanics to die of cancer (Shavers & Brown, 2002).  Based on these numbers, 
African Americans have an overall reduced life expectancy as compared to Caucasians 
and Hispanics.  Research describing cancer disparities has been conducted comparing 
African Americans to Caucasians with limited research evaluating disparities to other 
racial/ethnic groups (Saeed, et al., 2012).  Although cancer mortality has been decreasing 
in African Americans, the decrease has not been as great for African Americans as for 
Caucasians (Shavers & Brown, 2002).  And while there is a vast amount of literature to 
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document the existence of health disparities, there still has not been a significant 
reduction in the disparities seen between the racial/ethnic groups, indicating that 
additional research is needed in order to reach the goal of eliminating cancer disparities.   
Cancer incidence rates and mortality rates in Hispanics have been tracked since 
1992 (ACS, 2009).  Hispanics tend to have a lower incidence of cancer overall as 
compared to Caucasians, except for cervical and uterine cancer, liver cancer, and stomach 
cancer (ACS, 2009); however, Hispanics have cancer mortality rates similar to 
Caucasians for lung cancer (Shavers & Brown, 2002).  While the trends in cancer 
incidence and mortality in Hispanics have been followed for a much shorter period of 
time, studies have documented that racial disparities in treatment exists, although 
Hispanics are not studied as frequently as African Americans (Agency for Healthcare 
Research and Quality, 2012; Saeed et al., 2012; Betancourt & Renfrew, 2011; Smedley et 
al., 2003).  Therefore, this paper evaluated how NSCLC treatment paradigms compare 
across racial/ethnic groups including African Americans, Hispanics, and Caucasians and 
if these groups differ in the treatment received for advanced stage IIIB or stage IV first-
line metastatic NSCLC and if the patients are treated according to the current clinical 
practice guidelines. 
Non- Small Cell Lung Cancer and Treatment 
 NSCLC and small cell lung cancer (SCLC) are the two major types of lung 
cancer.  NSCLC is the more common and represents 85% of lung cancer cases and will 
be the focus of this paper.  There are several major cell histology that are used to describe 
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NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma 
representing 40%, 30%, and 15% of histology respectively (ACS, 2013).  
 Because there is not a routine screening test for lung cancer, approximately 75% 
of patients are diagnosed in the advanced stages of the disease when the prognosis is poor 
and is rarely curable (ALA, 2010; Hardy et al., 2009).  The treatment of NSCLC depends 
on the stage of the disease when diagnosed, on the patient’s performance status, and on a 
number of other factors.  Stage IV metastatic NSCLC is a cancer that has spread outside 
of the lungs to other parts of the body making the disease incurable (ACS, 2013).  
Patients with advanced stage metastatic NSCLC are usually treated with a platinum-
based doublet; the only recommended exception is a triplet combination with platinum 
based chemotherapy with bevacizumab for adenocarcinoma histology in appropriate 
patients.  The FDA approved agents for treating advanced stage NSCLC are cisplatin, 
carboplatin, paclitaxel, docetaxel, gemcitabine, pemetrexed, erlotinib, and bevacizumab 
(NCCN, 2013).  Other drugs are available to treat NSCLC according to the National 
Comprehensive Cancer Network guidelines, however they are not FDA approved.  
Radiation therapy in combination with a platinum agent is recommended in stage IIIB 
NSCLC.  Radiation alone may also be administered to patients with metastatic disease as 
palliation (NCCN, 2013).  As targeted therapies are approved for NSCLC, the treatments 
become more expensive and the treatment becomes more complex.  As these newer and 
more expensive therapies are incorporated into the clinical practice guidelines for use in a 
broader patient population, do all patients receive these agents as recommended?  This 
study evaluated the real-world treatment of patients with advanced/metastatic NSCLC to 
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determine if they were treated according to the recommended NCCN clinical practice 
guidelines. 
Clinical Practice Guidelines 
The IOM defines clinical practice guidelines as “systematically developed 
statements to assist practitioners and patient decisions about appropriate health care for 
specific clinical circumstances (Smedley, et al, 2003).” 
Clinical practice guidelines define the “gold standard” of treatment or best 
practices and provide health care professionals with the tools to provide high quality care 
based on the most current information and research from clinical trials.  Clinical trials 
provide the foundation for developing clinical practice guidelines in oncology; however, 
there are few minorities that participate in clinical trials.  Only 5% of African Americans 
and 1% of Hispanics participate in clinical trials today (Coakley et al., 2012).  Many 
African Americans still recall the Tuskegee experiment from the 1970s and have distrust 
for clinical trials (Gamble, 1997).  Clinical practice guidelines are an important part of 
cancer care as they can influence the physician’s decision for appropriate treatment and 
care, provide the physician with evidence gained from clinical research to reduce 
treatment variations between patients, potentially improve treatment outcomes, reduce 
morbidity and mortality, and can improve the quality of care (Woolf, Grol, Hutchinson, 
Eccles, & Grimshaw, 1999).  Disparity develops when clinical practice guidelines are 
followed for one patient population but not another population.  Clinical research 
conducted at Veteran Affairs hospitals demonstrated that when cancer patients are treated 
with similar therapy the outcomes are similar across patients regardless of socioeconomic 
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status (Shavers & Brown, 2002).  However, there is disagreement with the finding from 
the VA hospital findings as noted by Samuel, Landrum, McNeil, Bozeman, Williams, 
and Keating (2014).  Although patients may have the same clinical problem, patients may 
or may not receive the same treatment depending upon the location of the facility where 
the treatment is administered, the physician’s awareness of the clinical guidelines, and the 
physician’s clinical experience (McKinlay, Link, Freund, Marceau et al., 2007; Samuel et 
al., 2014).  McKinley et al. (2007) also noted that race and socioeconomic status had no 
effect on whether clinical practice guidelines were followed.  According to the NCCN 
guidelines, the current treatment for stage IV NSCLC is treatment with chemotherapy, 
radiation therapy, or a targeted agent such as bevacizumab (NCCN, 2013).  Treatment 
will depend upon the histology of the tumor, the location of the tumor, the number of 
metastases, and the patient’s overall medical condition (NCCN, 2013).  While stage IV 
lung cancer is not curable, treatment can improve the quality of life and extend survival 
for some patients. 
Clinical practice guidelines, when followed, have the potential to change 
healthcare providers’ behaviors, to improve the quality of care patients receive, and 
enhance the outcomes from treatment (Smith, 2000; Woolf et al., 1999).  The adoption of 
clinical practice guidelines tends to be dependent upon the quality and strength of the 
research to support the guideline, upon the physician attitude and type of practice, and 
upon the patient; however, an understanding of the influence of clinical practice 
guidelines on healthcare differences and disparities in NSCLC is limited (Graham et al., 
2011; Visser, Ma, Zak, Poulsides, Norton, & Rhodes, 2012).   
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Compliance to clinical practice guidelines varies (Hakkennes & Dodd, 2007).  
Factors that influence clinical practice guideline adherence include physician age and 
years of practice experience (McKinlay, 2007).  Grol and Grimshaw (2003) and 
Hakkennes and Dodd (2007) showed that up to 40% of patients are not treated according 
to practice guidelines and receive unnecessary treatment.  Foy et al. (2002) showed that 
when clinical practice guidelines are implemented and used there was an increase in 
physician compliance to following the guidelines.  There is evidence to suggest that 57% 
of patients with early stage NSCLC are treated with surgery then chemotherapy as 
recommended by the guidelines (Cancer Quality Council, 2013).  Bach (2005) suggests 
that African Americans receive care at facilities of lower quality and as such clinical 
practice guideline may not be followed.  When practice guidelines were followed, 
acceptance varied by the type of cancer (Harlan et al., 2005).  Harlan et al. (2005), Woolf 
et al. (1999), and McKinlay (2007) also suggest that following treatment guidelines can 
be used as a benchmark to improve the quality of care for patients.  Since clinical practice 
guidelines in oncology are generally updated yearly or as needed, following clinical 
guidelines provide healthcare providers with the ability to stay current with research 
progress and could help bridge treatment gaps (Li et al., 2011).  In addition, when 
patients are aware of the clinical practice guidelines they have the ability to make more 
informed decisions about their care and help improve quality of care.  Providing 
consistent care could reduce mortality and morbidity in cancer patients (Austin et al., 
2010; Evensen et al., 2010; Harlan et al, 2005; Li et al., 2011; Meyers, 2007).   
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The Guidelines for NSCLC 
 Clinical practice guidelines are used in a variety of healthcare environments from 
the physician, the nurse, to insurance payers for the objective of standardizing and 
improving the quality of care.  The guidelines provide the diagnosis, treatment, and 
palliative care for a variety of cancers, including NSCLC.  Clinical practice guidelines for 
NSCLC provide healthcare providers with the currently accepted treatments for patients 
based on the evidence from clinical trials.  The recommended guidelines for advanced 
stage IIIB or stage IV NSCLC were used as the basis for determining outcomes in this 
study.  The physicians’ treatment plan will depend upon the histology of the tumor, the 
location of the tumor, the number of metastases, and the patient’s overall medical 
condition (NCCN, 2013).  
 For stage IIIB NSCLC the recommended treatment is concurrent therapy of 
combined platinum-based chemotherapy with once daily radiation in patients with 
minimal weight loss (Jett et al, 2007).  The effect of radiation or chemotherapy alone is 
not as effective as the combination.  Treatment should be administered as soon as 
possible after diagnosis. 
For stage IV NSCLC, the patient usually has metastatic disease.  Approximately 
one third of patients will be diagnosed with a single brain metastasis where surgery 
followed by radiation to the brain is recommended (ACS, 2014).  Stage IV disease is 
present if there is the presence of a malignant pleural effusion.  According to the NCCN 
practice guidelines, the current treatment for stage IV NSCLC is chemotherapy, radiation, 
or a targeted agent such as bevacizumab (NCCN, 2013).  The guidelines recommend 
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treatment for 4 to 6 cycles or until disease progression.  The treatment of NSCLC 
depends upon the patients’ performance status, which is a known prognostic factor for 
improved survival (Azzoli, Giaccone, & Temin, 2010). While stage IV lung cancer it not 
curable, treatment can improve the quality of life and extend survival for some patients. 
Clinical Trials and Quality of Care 
 Clinical trials are the gold standard for providing evidence that defines the 
standard of care in cancer.  Oncology clinical practice guidelines are developed for use in 
the decision- making process of patient care using the evidence based on the results of 
large randomized controlled clinical trials and are used for improving the quality of 
patient care.  Accurate and timely reporting of clinical trial results is essential for 
determining the validity and credibility of the data and for establishing and maintaining 
quality care.  However, there is evidence that the reporting of clinical trial results in 
oncology is inadequate and inconsistent (Dancey, 2010; Schultz et al., 2010).  The 
Consolidated Standards of Reporting Trials (CONSORT) guidelines were established for 
reporting the essential elements to include for all clinical trial reporting (Maher et al., 
2010).  These elements include, for example, the name of the drug, the trial design 
details, the administration of the drug, the dosing, adverse events, and supportive care 
measures (Duff et al., 2010).  Research revealed that 11% of oncology clinical trials 
reported in top peer-reviewed journals included all the CONSORT elements for clinical 
trial reporting and less than half of the articles reviewed contained data about dose 
modifications for renal insufficiency or patient monitoring (Duff et al., 2010).  However, 
CONSORT does not include some of the complexities of administering chemotherapeutic 
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agents.  Clinical practice guidelines do provide the clinician with the most current 
oncology treatments and care and provide information for oncology drug reimbursement; 
however, there needs to be transparency and consistency in reporting the results.  The 
ability to provide consistent treatment and quality care in patients may help reduce 
disparities.    
Disparities 
A large amount of literature exists that reveals there are differences in healthcare 
treatment and in outcomes between Caucasians and African Americans based on 
socioeconomic status (SES).  Even when SES is controlled, disparities in health status 
still remain (Penner, 2007).  While there are data available to describe the differences in 
treatment and care for patients with cancer, the literature emphasizes the earlier stages of 
lung cancer disparities primarily and in African Americans compared to Caucasians (Yin, 
Morris, Allen, Cress, Bates, & Liu, 2010).  There are limited data evaluating the 
differences in healthcare among patients with advanced stage NSCLC and there is limited 
data in patients who are Hispanic. 
Potosky, Saxman, Wallace & Lynch (2004) evaluated the initial treatment of 
approximately 900 NSCLC patients across all stages of disease and found that overall 
52% of patients received the recommended treatment according to stage of disease as 
determined by the ASCO practice guidelines.  When treatment was stratified by 
race/ethnicity, African Americans and Hispanics received recommended therapy less 
frequently than Caucasians, 44%, 46%, and 53% respectively (Potosky et al., 2004).  
When patients were evaluated by stage of disease alone, patients with stage IV advanced 
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NSCLC received recommended initial treatment 41% of the time.  Potosky and 
colleagues suggested there might be gaps in quality of care for patients with NSCLC.   
In another study Shugarman and colleagues (2009) utilized the SEER database to 
evaluate treatment differences between race/ethnic groups with advanced NSCLC and 
found that half of the time appropriate and timely treatment was not given to African 
Americans with stage IV disease as compared to Caucasians (Shugarman et al. 2009).  
There were also differences in the timeliness of receiving therapy between race and 
gender and stage of disease at the time of diagnosis.  Overall, patients with stage III 
NSCLC were more likely to receive timely treatment (Shugarman et al., 2009). 
Previous research suggests there may be differences in treatment outcomes 
between patients.  From 1974-2001, the Southwest Oncology Group evaluated over 
19,400 cancer patients in 35 clinical trials, which included nearly 2700 patients with lung 
cancer to determine if racial disparities existed in overall survival (Albain et al, 2009).  
The study included an average of 11% African Americans.  Because patients were 
enrolled in clinical trials, there was consistency in the treatment received and in follow-
up for all patients.  While there were differences in overall survival reported between 
African Americans and Caucasians for certain cancers, there was no statistical association 
between race and overall survival for patients with NSCLC (Albain, et al, 2009).  Factors 
such as gender, age, weight loss, performance status at diagnosis, and stage of disease 
have been found to be associated with outcomes in patients with NSCLC (Blackstock et 
al., 2002).  In a study conducted between 1989 to 1999 by the Cancer and Leukemia 
Group B (CALGB) the effect of race/ethnicity on survival was retrospectively evaluated 
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based on 5 phase II and phase III clinical trials from various cancers (Blackstock et al., 
2002).  A total of 458 Caucasian and 46 African American patients with advanced stage 
IIIB or IV NSCLC were evaluated for survival.  Most patients completed a questionnaire 
providing their educational level, income, medical insurance coverage, and employment 
status prior to starting therapy.  African American patients were more likely to be 
unmarried, unemployed, lack insurance, and have a lower socioeconomic status, lower 
performance status and weight loss at diagnosis.  The results revealed that the estimated 
one-year survival for Caucasians was 30% versus 22% for African Americans.  When 
adjustments were made for weight loss and performance status, African Americans had 
greater weight loss than Caucasians, but this did not affect survival.  These authors 
concluded that while race/ethnicity did not affect survival, weight loss and performance 
status prior to treatment had a greater impact on treat outcomes.  In a Veterans Affairs 
Cooperative Study, no statistical difference in response rate or performance status was 
noted between African Americans and Caucasians with NSCLC treated with 
chemotherapy (Shavers & Brown, 2002).  Both African Americans and Caucasians 
experienced a similar 5-year overall survival rate; however, African Americans were 30% 
less likely to receive palliative care despite having equal insurance coverage (Shavers & 
Brown, 2002).  Advanced age has been found to be a predictor for physicians not using 
the clinical practice guidelines to determine treatment (Wang et al., 2012).  
Studies in early stage NSCLC evaluating disparities found that only patients with 
stage I, II or III NSCLC received appropriate therapy for stage of disease and that 
treatment was related to the age and race of the patient (Potosky et al., 2004).  In a report 
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by Bach and colleagues (2005b), African Americans with early stage NSCLC were less 
likely to have curative surgery than Caucasian patients despite having similar insurance 
and economic level.  A study from the University of Texas confirmed the results from 
Bach and others and found that African Americans received therapy according to clinical 
practice guidelines for early stage cancer 37% less often than Caucasians (Hede, 2010).    
Healthcare disparity in NSCLC among Hispanics is not well understood.  There 
are few studies in the literature that describe the disparities experienced by Hispanics in 
the treatment of lung cancer, and when Hispanics are included in the studies they are 
usually underrepresented (Saeed, 2012).  Two studies, one using the SEER database and 
the other study using the California Cancer Registry evaluated survival outcomes in 
Hispanics with NSCLC (Patel et al., 2013; Saeed et al., 2012).  Foreign-born Hispanics 
were compared to U.S. born Hispanics.  Patients were evaluated based on several 
confounders such as, age, gender, stage of disease, SES, and the neighborhood where 
they lived.  The results from these two studies demonstrated that foreign-born patients 
with NSCLC had a 13% to 15% (HR, 0.85- 0.87) lower mortality rate than patients born 
in the United States (Patel et al., 2013; Saeed et al., 2012).  When patients were evaluated 
by tumor histology, Hispanic patients were found to have either adenocarcinomas or 
bronchioalveolar (BAC) tumors.  BAC tumors have a more favorable profile and a lower 
mortality rate (Patel et al., 2013).  Lung cancer patients who were foreign-born were 40% 
more likely to be diagnosed at a more advanced stage of disease, at an earlier age, and 
less likely to receive treatment for their cancer (Patel et al., 2013; Saeed et al., 2012).  
U.S. born Hispanics had a lung cancer survival rate equivalent to non-Hispanic White 
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lung cancer patients (HR, 1.00).  While foreign-born Hispanics have a lower SES than 
U.S. born Hispanics, they still maintained a survival advantage over U.S. born Hispanics.  
One possible reason for the differences in survival between foreign born and U.S. born 
Hispanics could be the acculturation of Hispanics born in the United States or that 
foreign-born Hispanics return to their country of origin when they become too sick; but 
the survival patterns did not validate this trend (Patel et al., 2013).  A meta-analysis of 58 
studies from 1990 to 2010 showed that Hispanics with cancer have a survival advantage 
that is equivalent to non-Hispanic Whites  (Ruiz, Stefan, & Smith 2012). 
Insurance Status 
Insurance status has been shown to be a predictor for determining access to cancer 
care and receiving appropriate care (Shugarman et al., 2009; Ward et al., 2008).  
However, the evidence is mixed as there are few studies evaluating the association of 
insurance status and cancer treatment outcomes and even fewer studies specifically in 
lung cancer. During the past decade research has shown that patients who are 
underinsured or uninsured had worse treatment outcomes than patients with private 
insurance (Harlan et al., 2005; Niu et al., 2013).  Harlan evaluated the association of 
insurance and cancer outcomes in 11 different cancers and found that patients without 
insurance or patients with private insurance had better outcomes than patients with either 
Medicare or Medicaid.  An article recently published by Nui and colleagues (2013) found 
that between 1995-2004, cancer patients in New Jersey with Medicaid or who were 
uninsured had a higher risk of death than patients with private insurance.  These findings 
concur with a number of other studies previously conducted (Blackstock et al., 2002; 
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McDavid, Tucker, Slogett, & Coleman, 2003; Ward et al., 2008).  When Harlan et al. 
(2005) evaluated a variety of cancers for treatment according to the clinical guidelines 
and according to insurance status; they found that the type of insurance patients had 
influenced treatment according to the recommended guidelines.  Patients with private 
insurance were more likely to receive cancer treatment according to the guidelines 
regardless of race/ethnicity than patients on Medicaid or Medicare (Harlan et al., 2005).  
Patients with Medicaid insurance only were the least likely to receive therapy according 
to the guidelines while patients with no insurance or private insurance were most likely to 
receive treatment according to the clinical treatment guidelines, 70%, and 65% 
respectively.  Blackstock et al. (2006) and ascribed that when insurance status, economic 
status, stage of disease, and age are equal, treatment for early stage NSCLC with 
chemotherapy and/or surgery outcomes are similar.   
To answer the question of which factors have a greater influence on patient’s 
healthcare, Trevedi et al. (2006) investigated whether the quality of the insurance plan or 
the race/ethnicity of the patient affected health outcomes more.  Trevedi et al. examined 
health records from over 400,000 patients on over 150 Medicare plan between 2002-2004 
for quality and performance and revealed that neither the insurance plan nor the quality or 
performance contributed to disparities.  Despite having the same insurance plan, 
significant disparities were found between African American and Caucasian health 
outcomes (Trevedi et al., 2006).  Halpern et al (2008) also found that insurance status 
influenced cancer treatment and that individuals over 65 years of age with Medicare do 
not receive equal treatment, even though the stage of cancer at the time of diagnosis was 
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similar across insurance types.  In a second study, Halpern and Holden (2012) found that 
insurance status also influenced the timeliness of cancer treatment; African Americans 
and Hispanics were found to experience treatment delays more often than Caucasians.  
Patients having both Medicaid and Medicare coverage still experienced delays in 
treatment.  When universal insurance coverage is available, disparities still exist in cancer 
treatment (Li et al., 2011).  Yorio et al. (2012) indicated that when patients are treated at 
VA Hospital or an NCI designated cancer center differences in overall survival appear to 
disappear.  Differences in insurance status may contribute to cancer outcomes; however, 
additional research is needed in this area to overcome the disparities in care experienced 
by patients with lung cancer  (Halpern & Holden, 2012). 
A robust example for comparison is the medical system for the U.S. military, 
which provides unlimited and equal access to healthcare and can provide an opportunity 
to evaluate healthcare disparities under equal conditions.  In an effort to evaluate if there 
is disparity in lung cancer survival between men and women and between race/ethnicity 
of military personnel, Mulligan et al (2006) conducted a retrospective chart review of 907 
NSCLC patients treated at Walter Reed Medical Center from 1990 to 2000.  Patient 
survival was analyzed by age, gender, race/ethnicity, family history of cancer, smoking 
history, stage of disease, and lung cancer histology.  The overall survival of NSCLC 
patients treated at Walter Reed Army Medical Center were compared to the overall 
survival of NSCLC patients in the SEER database for 2000.  The overall 5-year survival 
at Walter Reed was higher than the 5-year national average for survival in the SEER 
database, 22.4% versus 15.2 % respectively (Mulligan et al., 2006).  The 5-year survival 
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for African Americans versus Caucasians was essentially equal at 22.3% versus 22.7%.  
Even when survival was evaluated by gender, survival was higher for the Walter Reed 
Army Medical Center patients compared to the national average in SEER.  Gender was 
the only factor that affected 5-year overall survival with females having a longer survival 
than males, 28.9% versus 19.4% (Mulligan et al, 2006).  Mulligan and colleagues suggest 
that when there is equal access to healthcare, health outcomes are equal implicating a 
lack of access to medical care as a cause for racial/ethnic disparities.  A larger study 
conducted by the Department of Defense using their central tumor registry database 
confirmed the results of Mulligan and colleagues indicating that NSCLC survival is 
higher in a military facility than the general population and that equal access to care may 
eliminate health disparities (Zheng et al., 2012). 
Which factors are contributing to lung cancer disparities and how these factors 
affect each other remain unclear.  Lung cancer treatment appears to vary by place of 
treatment, utilization of health care services, institutional policies, race/ethnicity, gender, 
and socioeconomic status.  Having standards of care established and guidelines in place 
may help to eliminate some of the differences in treating NSCLC and reduce healthcare 
disparities. 
Socioeconomic Status, Race, and Environmental Factors 
 There are considerable data in the literature documenting that race and 
socioeconomic status affect mortality; however, there is less data on how these factors 
impact cancer mortality in patients with lung cancer.  Albano et al. (2007) sought to 
determine if there was a relationship between education, race/ethnicity, and mortality in 
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cancer patients, including lung cancer, by using U.S. census data and death certificates 
from African American/Black and Caucasian cancer patients in 47 states.  Overall, the 
death rate for African Americans was higher than for Caucasians at comparable 
educational level.  Albano and colleagues contribute the difference in mortality to the 
differences in overall socioeconomic status between the two groups (Albano et al., 2007).  
When lung cancer mortality was evaluated, the difference between African American and 
Caucasian patients by educational attainment was greater than for other cancers that were 
evaluated.  Patients with an educational level of 0 to 8 years had a mortality rate that was 
nine times higher than patients with educational attainment of 17 or more years and was 
higher in African American men and women as compared to Caucasian men and women 
(Albano et al., 2007).  Albano and colleagues (2007) found a stronger association 
between educational level and cancer mortality than in previous studies.   
There are considerable data to show that the geographic area one lives in 
influences the quality of health care and mortality (Myers, 2007).  Research suggests in 
areas of low socioeconomic status that there may be fewer resources available, that the 
healthcare providers maybe less educated and that patients may not receive timely and 
appropriate therapy (Goulart et al., 2013).  Referrals to medical specialists have also been 
shown to influence cancer care.  Patients in a lower socioeconomic group are also less 
likely to be referred to an oncologist or to receive recommended therapy as compared to 
patients in a higher socioeconomic group (Goulart et al., 2013; Freeman & Chu, 2005).  
Life expectancy, the geographic location, the number of healthcare providers in an area, 
and treatment variation play a role in healthcare treatment and can contribute to the 
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disparities experienced by minorities (Meyers 2007; Watson, 2001).   
Cognitive Factors 
A healthcare providers’ perception can affect the care patients receive.  According 
to the SCT, physicians contribute to health disparities through stereotyping and bias that 
reflects in the quality of care (Smedley, 2003; Burgess et al., 2004).  The SCT theory 
suggests that the healthcare providers understanding of the information provided by the 
patient and how the information obtained is interpreted may contribute to racial/ethnic 
differences in care and outcomes (Meyers, 2007; Burgess et al., 2004).  Consciously or 
unconsciously healthcare providers express biases and categorize individuals according 
to characteristics, social categories, and stereotypes (Burgess et al., 2004).  Healthcare 
providers also make judgments about how a patient will follow through with treatments 
(Burgess et al., 2010).  Several studies revealed that Caucasian healthcare providers 
perceive African Americans as having less family support and as being less compliant to 
treatments long-term (Bogart et al., 2004; van Ryn et al., 2003). 
When physicians process large amounts of complex information to make clinical 
decisions, they tend to act on what they have already learned and already know, 
especially when there may be insufficient information available about the best treatment 
to provide to a patient thereby causing the potential for errors in diagnosis and treatment 
(Freeman & Chu, 2005; Burgess et al, 2004).  These decisions in turn also have the 
ability to affect the communication between the clinician and the patient and adherence to 




According to the SCT, an individual’s behavior is influenced by the behaviors and 
thoughts of others’ around them (Pajares, 2002).  Studies in SCT have examined 
healthcare provider behaviors to understand how race/ethnicity affects treatment.  
Physician treatment patterns are influenced by their medical training, background, by the 
variety of medical experts whom they interact, by their mentors, by medical ethics, and 
by other colleagues (Smith, 2000).  In addition, stereotypes by healthcare providers have 
been shown to influence the patient.  If a patient feels they are being discriminated 
against or the physician exhibits anxiety, the patient may not communicate openly with 
the physician, may not share information about their illness, and may even be less 
complaint to treatments (Burgess et al., 2010; Smith, 2000).  Blair et al. (2013) conducted 
telephone interviews with patients to determine the perception and satisfaction with their 
physician.  African Americans consistently reported more bias on the part of the 
physician and more dissatisfaction with care.  Hispanics/Latinos did not report bias but 
consistently rated the physician lower on knowledge of their health concerns, medical 
history, and interpersonal skills (Blair et al., 2013).  Providing continuity of care through 
the use of clinical practice guidelines may improve the quality of care patients receive 
(Penner et al., 2007). 
Tumor Boards 
 Tumor boards serve an important role in cancer programs and there are data 
reported that they might improve cancer care (Scher et al., 2011).  Tumor boards bring 
physicians and other healthcare providers together from medical oncology, radiation 
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oncology, pathology, radiology, surgery, and other allied health specialties to discuss the 
management and care of the newly diagnosed patient.  Physicians from their respective 
discipline present the current treatment strategies appropriate for the patients’ cancer and 
discuss the current clinical trial data to help guide the treatment course for the patient.  
All NCI designated cancer programs have either general or tumor specific tumor boards 
as required by the American College of Surgeons Commission on Cancer Program 
Accreditation but their effect on cancer care has not been well studied. (Keating et al, 
2012).  Some controversy exists as for the value of tumor boards improving quality care 
based on the physician recommendations provided from the tumor board.  The 
Department of Health Policy at Harvard Medical School evaluated the association 
between the recommendations, quality of care and outcomes of patients in 138 Veterans 
Administration (VA) Hospitals and physicians attending tumor boards and found there 
was little to no association between physicians attending tumors boards, between the 
recommended treatment patients received and outcomes (Keating et al., 2012).  Other 
researchers have noted that tumor boards may not influence physician treatment and 
outcomes in large institutions, but may be more effective in small cancer centers 
(Blayney, 2012).  However, Scher (2011) found that over 80% of physicians attended 
tumor boards when they are offered and that tumor boards provide a way for physicians 
to discuss the treatment of difficult patient cases as a way to improve the quality of care 
(Scher, 2011).  Physicians with high volume practices, treating 25 or more new patients 
per month were more likely to attend tumor boards (Scher, 2011).  Additional research is 
still needed to determine the characteristics of the physicians attending tumor boards and 
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the influence of tumor boards on physician treatment patterns and clinical guideline 
adherence (Blaney, 2013; Keating et al., 2013; Scher, 2011). 
 Addressing treatment differences and disparities in lung cancer is complex and 
involves multiple factors that cannot be defined by one theory.  Preliminary research in 
NSCLC healthcare disparities is mixed and this suggests that further research is needed.  
If practice guidelines are available and followed to influence clinical decision making, 
there may be fewer disparities seen between races/ethnicities.   
While most of the research regarding disparities in lung cancer is focused in the 
earlier stages of the disease and compares African Americans and Caucasians, this 
research study will address how the current treatment guidelines available for NSCLC 
guidelines are used in a population-based patient population that includes Hispanics.  
Hispanics continue to rapidly increase in the United States yet represent a smaller 
percentage of the patients in the SEER database.  To gain a better understanding of the 
treatment paradigms’ within this ethnic group they should be included in treatment and 
disparities research.  This research study will include an evaluation of Hispanic patients 
with advanced metastatic NSCLC since there is little research about the treatment 
paradigms of these patients.  
 This research study will build on what is currently known about treating advanced 
stage NSCLC in a diverse population of Hispanics, African Americans, and Caucasians.  
Specific chemotherapy and targeted therapies will be evaluated for their use in NSCLC 
and if they are used according to the current clinical practice guidelines within each of 
the racial/ethnic groups. 
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Summary and Conclusions 
This chapter describes some of the multiple factors involved in healthcare 
disparities. Although research has been conducted on cancer disparities, the causes for 
these disparities still are not well understood, particularly among Hispanics.  The SCT 
and Bandura’s self–efficacy model suggest that physicians unconsciously contribute to 
health disparities.  Previous research on disparities in lung cancer has been conducted on 
the comparisons between African Americans, who have the greatest lung cancer burden, 
to Caucasians in the earlier stages of the disease.  The research also revealed that despite 
equal socioeconomic status and equal insurance coverage differences in cancer care and 
outcomes remain.  There is limited data studying the treatment paradigms and differences 
in treatment and care among Hispanics and African Americans as compared to 
Caucasians in the later stages of NSCLC.  This study will attempt to fill the gap and focus 
on evaluating the use of lung cancer clinical treatment guidelines in patients with 
advanced/metastatic NSCLC between Hispanics, African Americans, and Caucasians.  
This study has considered the limitations and will therefore evaluate patients for 
treatment patterns and to determine if there is a relationship between race/ethnicity and 
lung cancer treatment according to the NCCN clinical practice guidelines.  
Since healthcare professional’s training and behaviors have been shown to 
contribute to the disparities, having clinical practice guidelines available to physicians 
treating patients is a first step in an attempt to reduce racial and ethnic differences in the 
treatment of disease.  Having an understanding of the extent to which NSCLC clinical 
practice guidelines are consistently used across racial/ethnic groups, this research study 
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may help to bring us closer to reducing the cancer burden in the United States and 
improving care for all patients.    
Chapter 2 provided the background on healthcare disparities and the literature as 
it related to the research questions and hypotheses, and the objective of the study.  
Chapter 3 outlines the quantitative research methodology that was used for this study.  A 
description of the study hypotheses based on the research questions will be explained.  A 
description of the retrospective research design, the dependent, and independent study 
variables, a description of the NCI database that was used, the techniques for the data 
collection, and data analysis are included.  The determination of sample size and a 
description of the patients are explained.  The relationship between race/ethnicity for 





Chapter 3: Research Method 
Introduction 
Lung cancer is a major killer in the United States with approximately 155,000 
patients dying from the disease each year (ACS, 2014).  It is primarily a disease of the 
elderly with over 60% of patients diagnosed with lung cancer over 65 years of age 
(Foster, Salinas, Mansell, Williamson, & Casebeer, 2010).  With the complexities of 
treating lung cancer and the new diagnostic technologies being developed, clinical 
treatment guidelines constantly need to be updated to include the newest research 
discoveries, physicians need to be aware of the updates and be able to incorporate the 
guidelines to their clinical treatment decisions. 
In this chapter, I provide an overview of the research methodology used in this 
study to test the hypotheses and answer the research questions around the first-line 
treatment for NSCLC in three racial and ethnic groups according to the NCCN treatment 
guidelines.  I also describe the research hypothesis and questions.  In addition, a 
description of the study population, the procedures for selecting the sample population 
and determining the sample size, a description of the inclusion and exclusion criteria, an 
explanation of the study variables, and details of the statistical plan are provided.  This 
chapter also includes a discussion of issues pertaining to reliability and validity of the 
study and the data collected from the SEER/Medicare database.  The chapter concludes 
with the ethical considerations for this research. 
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Purpose of the Study  
 The purpose of this retrospective quantitative study was to evaluate the 
differences among Caucasian, Hispanic, and African Americans with NSCLC within 
strata as defined by stage and histology and the receipt chemotherapy for the first-line 
treatment of advanced/metastatic NSCLC treatment according to clinical practice 
guidelines while controlling for age and gender.  For this study, patients were stratified 
into four groups: (a) stage IIIB disease and adenocarcinoma; (b) stage IIIB and squamous 
cell carcinoma; (c) stage IV disease and adenocarcinoma; and (d) stage IV disease and 
squamous cell carcinoma. 
Research Design and Rationale 
Research Question 
To understand the association between race/ethnicity and the receipt of first-line 
treatment of advanced/metastatic NSCLC according to the recommended NCCN clinical 
practice guidelines for stage and histology strata, the following research question was 
asked: What is the likelihood of Caucasian, African American, and Hispanic patients with 
NSCLC being equally treated according to the NCCN practice guidelines within stage 
and histology strata after controlling for age and gender?   
 Evidence suggests that there may be an association between race/ethnicity and the 
receipt of first-line therapy for advanced/metastatic NSCLC and physicians following 
clinical practice guidelines.  Therefore, the following hypotheses were evaluated. 
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Null and Alternative Hypotheses 
1.  Ho: Caucasian and African American patients with NSCLC are equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age and gender, and geographic location. 
      H1: Caucasian and African American patients with NSCLC are not equally likely to 
be treated according to the NCCN treatment guidelines within stage and histology after 
controlling for age and gender, and geographic location. 
2.  Ho2: Caucasian and Hispanic patients with NSCLC are equally likely to be treated 
according to the NCCN treatment guidelines within stage and histology strata after 
controlling for age, gender, and geographic location     
       H12: Caucasian and Hispanic patients with NSCLC are not equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age, gender, and geographic location 
3.    Ho3: Hispanic and African American patients with NSCLC are equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age, gender and geographic location     
       H13: Hispanic and African American patients with NSCLC are not equally likely to 
be treated according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age, gender, and geographic location 
Dependent and Independent Variables 
 The dependent variable for this study was receipt of first-line treatment with 
chemotherapy according to NCCN treatment guidelines (i.e., receiving either taxane plus 
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platinum, gemcitabine plus platinum, pemetrexed plus platinum, or the triple combination 
of bevacizumab plus platinum-based therapy for stage IV NSCLC and platinum plus 
etoposide alone or concurrent radiation and platinum plus etoposide for stage IIIB 
NSCLC based on histology).  The predictor variables were age (65-70, 71-75, 76-80, 81-
85, and 85 and older), gender (male, female), and race/ethnicity, which were recorded as 
Caucasian, African American, or Hispanic (see Table 1).  Patients were stratified by stage 
of disease and histology into four groups: stage IIIB disease with either adenocarcinoma 
or squamous cell carcinoma and stage IV disease with either adenocarcinoma or 
squamous cell carcinoma.  Stage IIIB NSCLC was defined as patients with disease that 
has spread to the lymph nodes near the collarbone or to the nodes on the opposite side to 
the tumor, patients with a pleural effusion, or with disease that has spread to other areas 
within the chest, such as the esophagus or trachea.  Patients with stage IV NSCLC have 
disease that has spread outside of the chest wall to other parts of the body such as the 
bone, liver, or brain, or has spread to other distant lymph nodes.  Recommended and 
appropriate therapy for stage IIIB NSCLC is radiation plus chemotherapy or 
chemotherapy alone.  Recommended therapy for stage IV NSCLC is a doublet 
combination of chemotherapy (NCCN, 2014).  There are no recommendations for the 
administration of a specific chemotherapy with the exception of pemetrexed, which is 
indicated for adenocarcinoma histology and gemcitabine for squamous cell histology 
(NCCN, 2014). Although the approach to treating older cancer patients is unclear, age 
has been found to be an influencing factor in treating patients with advanced/metastatic 
NSCLC.  The benefits of treatment outweigh the risk, yet many cancer patients are 
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undertreated (Foster et al., 2010).  Foster et al. reported that patients over the age of 78 
were less likely to receive standard chemotherapy than patients younger than 60 years of 
age, despite being in relatively good health.  While there is not a specified time period in 
which treatment should be initiated, starting therapy as soon as possible after diagnosis, 
usually within a month, has been shown to improve outcomes (Yorio et al., 2009).  
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Adherence to NCCN Clinical Practice Guidelines 
 Adherence to the NCCN clinical practice guidelines for this study was based on 
the patient stage of disease and tumor histology.  Most patients with stage IIIB disease 
are not eligible for surgery; therefore, treatment is based on the patient’s extent of 
disease, performance status, and co-morbidities.  Because performance status is not 
captured in the SEER-Medicare database, patient histology and extent of disease based 
on stage of lung cancer was used to determine appropriate treatment.  The NCCN clinical 
treatment guidelines recommend concurrent radiation, platinum, and etoposide or 
radiation with paclitaxel and platinum chemotherapy for patients with stage IIIB NSCLC 
(Figure 1). The recommended dose of radiation is 60-70 Gy over 6-7 weeks.  Radiation 
alone can be used as palliation to treat pulmonary symptoms such as pain or shortness of 
breath (NCCN, 2013).  Based on the clinical data nonplatinum-based chemotherapy does 
not provide a treatment benefit over platinum based therapy (Lwin, Riess, & Gandara, 






Figure 2.  Treatment Algorithm for Stage IIIB NSCLC based on the NCCN NSCLC 
Guidelines. 
 
Patients with stage IV NSCLC have metastatic disease at the time of diagnosis.  
The goal of treatment is to extend survival and palliate symptoms from the disease 
(NCCN, 2014). Performance status is one of the most important prognostic factors for 
outcomes; however, performance status is not currently captured in the SEER-Medicare 
database. Therefore, treatment according to the recommended treatment guidelines was 
determined by histology.  The NCCN treatment guidelines recommend a platinum-based 
chemotherapy doublet as first-line treatment of stage IV NSCLC; however, there are no 












Figure 3.  Treatment Algorithm for Stage IV NSCLC based on the NCCN NSCLC 
Guidelines. 
 
Treatment for stage IV NSCLC is recommended for four cycles and if the patient 
is responding may receive two additional cycles, for not more than a total of six cycles of 
therapy in the first-line setting.  A triple combination of paclitaxel, carboplatin, and 
bevacizumab is recommended for patients with nonsquamous histology 
(adenocarcinoma) if the patient does not have a centrally located lung tumor.  However, 
other triplet combinations are not recommended because of the added toxicity and have 
not been found to offer a survival advantage over the doublet regimens (NCCN, 2014). 
The combination of pemetrexed plus platinum chemotherapy is recommended for 















patients with adenocarcinoma, whereas gemcitabine or a taxane plus platinum 
chemotherapy is recommended for patients with squamous histology (Azzoli et al, 2011).  
Radiation is recommended for patients with stage IV NSCLC for palliation of symptoms 
from the disease, such as bone metastases or for brain metastases (NCCN, 2014).  The 
NCCN clinical practice guidelines for stage IIIB and IV NSCLC have change overtime.  
The two differences from 1998 to 2014 are that histology matters.  Patients are now 
treated differently based on the histology of the tumor and the duration of treatment for 
stage IV NSCLC was shortened in 2003 from a maximum of eight cycles of therapy to no 
more than six cycles of therapy.  If the patient is not responding to therapy it should be 
stopped at four cycles.  
 Treatment information for up to 6 months after diagnosis was confirmed based on 
the International Classification of Disease 9th edition Clinical Classification (ICD-9-CM) 
procedure codes and certain ICD-9-CM codes for lung cancer diagnosis, International 
Classification of Disease for Oncology, third edition (ICD-O-3) code was used for 
NSCLC (8046), as well as SEER therapy codes, and revenue codes in the Medicare 
database.  Chemotherapy administration codes for each chemotherapeutic agent, 
cisplatin, carboplatin, gemcitabine, pemetrexed, bevacizumab, paclitaxel, and docetaxel 
were used to determine treatment against the NCCN clinical guidelines.  If a patient 
received a claim for concurrent cisplatin, etoposide and radiation or cisplatin plus 
etoposide on the same date of service they were considered to have received therapy 
according to the NCCN clinical practice guidelines.  For stage IV disease, if a patient 
received a claim on the same date of service for a combination of cisplatin plus a taxane, 
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pemetrexed plus platinum, gemcitabine plus platinum or a taxane plus platinum plus 
bevacizumab they were considered to have received treatment according to the NCCN 
clinical practice guidelines. 
Methodology 
Population Characteristics 
 To be included in the study patients had to have a confirmed diagnosis of 
NSCLC, have stage IIIB/IV NSCLC, and be age 65 years or older at the time of 
diagnosis.  Patients were of Caucasian, African American, or Hispanic race/ethnicity and 
stratified based on stage of disease and histology into four groups.  The four groups will 
be stage IIIB with adenocarcinoma or squamous cell carcinoma and stage IV disease with 
adenocarcinoma or squamous cell carcinoma.  Other factors that were adjusted for based 
on treatment were gender and age to determine the influence of these variables on the 
likelihood of receiving first line treatment according to the NCCN clinical practice 
guidelines.  All patients were covered only by Medicare insurance at the time of 
diagnosis as patients covered by a HMO or other type of insurance may have different 
patterns of care.   
Sampling Procedures 
 Patients were extracted from the linked SEER-Medicare database.  A total of   
250,045 lung cancer patients were included in the SEER-Medicare database.  In order to 
draw valid conclusions about the data from this study the following statistical parameters 
were applied.  The sample for this research consisted of all Medicare patients age 65 
years or older who were diagnosed with NSCLC between 1998-2010 and filed a 
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Medicare claim during this same time period.  Patients were selected based on the 
International Classification Disease for Oncology (ICD-O-3) code for NSCLC.  SEER 
provides data on patient demographics, cancer stage, histology, and date of diagnosis.  
Medicare claims provide chemotherapy administered, and first treatment beginning and 
ending dates. The month and year were used to determine date of diagnosis.  The 
MEDPAR, physician, and DME claims data were used to gather information about 
chemotherapy treatment.  The NCH files were used to find radiation claims.  The dose of 
radiation received was not provided but the duration of therapy was provided.  Nursing 
home records, health maintenance organization records, and Medicare denied claims 
were omitted from the MEDPAR database.  The drug specific codes were identified for 
paclitaxel, docetaxel, cisplatin, carboplatin, pemetrexed, gemcitabine, vinorelbine, and 
bevacizumab as well as the treatment code for radiation. Patients were coded as “yes or 
”no” as having received the recommended treatment combination in the first-line setting 
or did not receive recommended combination treatment. 
Sample Size and Statistics 
 The study objective was to detect whether a statistically significant difference 
exists between race/ethnicity within strata defined by tumor stage and histology, 
according to the first line treatment of NSCLC according to the NCCN clinical practice 
guidelines while controlling for age and gender.  This study used multivariable logistic 
regression to determine if there were differences in the first line treatment of lung cancer.  
Regressions models were developed for each of the strata of stage and histology. A 
binary logistic regression model was appropriate as the dependent variable is 
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dichotomous and there were one or more independent variables.  To determine if a 
statistically significant difference existed the statistical power, alpha, and effect size was 
determined.  A high statistical power improved the chance that the results were not due to 
chance alone.  The minimum accepted value for power (1-ß) is 80% (0.8) meant that 
there was an 8 out of 10 chance of rejecting the null hypothesis.  The alpha for this study 
was set at .05 for a two-tailed test, which meant there was be a 95% chance the correct 
conclusion will be reached.  The confidence level was set at 95% and statistical 
significance p < 0.05.  An adjusted odds ratio (OR) representing the odds for receiving a 
given treatment type by race/ethnicity as a function of age, stage of disease and histology 
was determined, and the corresponding 95% confidence interval (95% CI) was 
calculated.  If the OR was statistically equivalent to “one” or unity (e.g., 95% CI for the 
adjusted OR contains 1 and the p value for the adjusted OR is greater the 0.05) there was 
a difference for a particular treatment as the first line therapy between two racial/ethnic 
groups.  If the OR was statistically different from “one” or unity (e.g., 95% CI for the 
adjusted OR does not contain 1 and the p value was less than 0.05) there was a difference 
for a particular treatment type in the first line setting between racial/ethnic groups.  All of 
these statistical parameters were the standard norm in epidemiologic and biomedical 
research (Dakhale, Hiware, Shinde, & Mahatme, 2012).  G* Power was the statistical tool 
to determine power analyses and effect size for a variety of statistical tests (Faul, 
Erdfelder, Buchner, & Lang, 2009).  Power analysis for a logistic regression was 
conducted using the G*Power 3.1 statistical power calculator to determine the sample 
size based on an alpha = 0.05, ß = 0.80, 2-sided tails, and an odds ratio = 1.44.  To detect 
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a small size effect an odds ratio of 1.44 was assumed (Nandy, 2012).  This study 
provided adequate number of patients and power to detect a difference between 
race/ethnicity.  
Data Source  
The NCI SEER/Medicare database links the demographic and tumor data from 
the SEER database with the Medicare claims filed from the CMS.  SEER collects data 
from 18 cancer center registries throughout the United States that represents 28% of the 
U.S. population (NCI, 2013).  SEER data are available from 1973 to 2013 and Medicare 
data are available from 1991 to 2010 (NCI, 2013).  The patients selected for inclusion in 
this study were diagnosed with stage IIIB/IV NSCLC from 2009 to 2013.  Patients 
diagnosed by a death certificate were not included.  SEER data are available for patient 
age, gender, race/ethnicity, tumor site, stage of disease, tumor histology, date of 
diagnosis, and initial treatment.  All Medicare claims have fields for race, gender, date of 
service, as well as diagnostic and procedure codes (Warren et al., 2002).  In addition, the 
SEER-Medicare claims data include claims from the hospital, outpatient clinics, 
physicians, home healthcare, and hospice providers (Warren et al, 2002).  Medicare 
claims data were used to obtain the specific chemotherapy administered.  SEER-
Medicare data are available for 93% of participant’s age 65 or older (NCI, 2013, Engels 
et al., 2011).  Ninety-six percent of individuals enrolled in Part A Medicare also have Part 
B Medicare coverage, which covers physician and outpatient services (NCI, 2013).  The 
Medicare claims data were used to identify the chemotherapy administered.  The 
individual drug codes were used to identify chemotherapy administration.  Using this 
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large database will provide a better understanding of real world patterns of care among 
NSCLC patients of different races/ethnicities and is more representative of the elderly 
population who carry most of the burden of NSCLC.  The SEER database does not 
collect data from patients with Medicare as a second insurer, patients enrolled in an 
HMO, or patients receiving care at a Veteran Administration Hospital (NCI, 2012). 
Inclusion Criteria 
Patients from the SEER-Medicare database were included in the study if they had 
a confirmed diagnosis of NSCLC from 1998–2010, were age 65 years or older, were 
treated within 6 months of diagnosis, and if there was at least one claim filed for 
chemotherapy.  The characteristics of the study cohort for inclusion to the study are,   
1. Age, 65 years and older 
2. Gender, male and female 
3. Race, Caucasian, African American, and Hispanic 
4. Histology, adenocarcinoma and squamous cell carcinoma 
5. Stage of disease, stage IIIB and stage IV 
 Patients in the SEER database were excluded from study if they were diagnosed 
with NSCLC before the age of 65 years.  Patients younger than 65 years of age were not 
included in the Medicare database however they may be included in the SEER database.  
Most patients with lung cancer were diagnosed with advanced stage disease, as such, 
patients with a diagnosis of stage I, II, or IIIA NSCLC at age 65 were excluded from the 
study cohort.  Patients with a diagnosis of NSCLC prior to the enrollment in Medicare 
were excluded as they may be treated differently from Medicare patients.  Patients with a 
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diagnosis of small cell lung cancer, a concurrent cancer, or any other previous cancer 
were excluded.  Patients with end-stage renal disease or a medical disability are covered 
under Medicare; however, these patients were excluded from this study.  Patients with 
missing data for any of the study variables were categorized as unknown and not included 
in the analysis, i.e., there was not imputation for missing data.  Patients of Asian, 
American Indian/Native Alaskan, Native Hawaiian, or other Pacific Islander 
race/ethnicity were not included in the study cohort.  The Alaska and Arizona registries 
were excluded from analysis as SEER only captures information on American Indian and 
Alaska Natives in these states (NCI, n.d.). 
Gaining Access to the Data 
 The SEER-Medicare database is a large population cohort of cancer patients that 
allows for the longitudinal study of treatment procedures and treatment administration.  
The database has been used extensively for disparity research and outcomes research and 
is a standard tool that researchers use to evaluate patterns of care and outcomes in 
oncology (Clegg et al., 2007).  The database is also used for studies in public health 
policy and planning (Engels et al, 2010; NCI, 2010).     
 Because the SEER-Medicare linked database is not open to the public permission 
must be granted for its use in research and to also maintain the confidentiality of the 
patients and the healthcare providers.  The SEER- Medicare data set is considered a 
limited dataset by Health Insurance Portability and Accountability Act (HIPPA) and as 
such a data use agreement for requesting lung cancer data was signed by the committee 
chairperson and myself prior to receiving access to the SEER-Medicare files.  A Walden 
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IRB approved proposal was submitted to the SEER-Medicare reviewers for approval 
prior to the release of the requested databases. 
Data Analysis 
 A multivariable logistic regression was conducted to analyze the data from the 
SEER-Medicare database, using the Statistical Packages for the Social Science (SPSS).  
Baseline demographics and patient clinical characteristics were analyzed using measures 
of central tendency (e.g., means, medians) and spread (standard deviations, SD; range) 
and frequency counts and percentages for categorical variables (e.g., gender).  
Race/ethnicity, age, and gender were the independent variables that determined the 
treatment in the first line setting.  The dependent variable was dichotomous and defined 
as either “yes” or “no” (e.g., patient received taxane plus platinum vs. patient did not 
receive taxane plus platinum).  Patients were stratified according to stage of disease and 
histology and within each strata age and gender were controlled. Univariate and 
multivariate regression analysis were performed to compare the likelihood of receiving 
treatment according the practice guidelines within stage and histology strata.  A 
regression analysis tested if the criterion variable was linearly related to the covariates of 
age and gender.  In order to understand the variance in the dependent variables a table 
was developed for R2.  A classification table was developed to estimate the percent of 
cases correctly classified as receiving first-line treatment with each independent variable 
added to the model, the probability of the outcome occurring, the sensitivity, and 
specificity.  A third table showed the contribution of each independent variable to the 
regression model and its statistical significance.  The p values were evaluated for each 
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covariate to determine the statistic evidence for the contribution to the model.  The OR 
indicated the likelihood of receiving the recommended treatment based on the clinical 
practice guidelines and based on the independent variables.  The confidence intervals 
were established using the odds ratio.  The final logistic regression model pooled the 
observations according to probabilities assessed with the goodness-of-fit statistic (Homer 
& Lemeshow, 1989).  Missing data was not included in the final analysis thereby 
allowing for a complete case analysis to be conducted (Piggott, 2001).  This study was 
exploratory in nature and therefore there was no adjustment for multiplicity.  It was 
recognized there was the potential for inflated type I error; this is discussed in Chapter 5.  
All statistical analyses were performed using IBM SPSS 23.0 (IBM SPSS Statistics 23.0 
August 2016, Armonk, NY). 
Instrumentation and Operationalization Constructs 
   The NCI’s SEER database is the one of the largest population-based cancer 
databases in the U.S. and is considered that standard for quality among cancer registries 
(NCI, 2010).  Since 1972 SEER has collected data and monitored cancer trends, cancer 
incidence, diagnosis, therapy, and survival (NCI, 2010).  SEER collects cancer data from 
select state tumor registries (Alaska, Arizona, California, Connecticut, Georgia, Hawaii, 
Iowa, Kentucky, Louisiana, Michigan, New Jersey, Utah, and Washington) that cover 18 
geographic regions to represent the diverse population in the U. S (NCI, 2010; Engels et 
al, 2010).  While the database may represent the diverse race/ethnicities in the United 
States, the database tends to represent more urban than rural areas (Engels et al, 2010).  
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SEER also contains slightly more foreign-born cases (18%) as compared to13% in the 
general U.S. population (NCI, n.d.).   
Reliability and Validity 
 The SEER-Medicare database allows for the longitudinal study of treatment 
procedures and treatment administration.  The database has been extensively used for 
disparity research and outcomes research and is a standard tool that researchers use to 
evaluate patterns of care and outcomes (Clegg et al., 2007).  The database is also used for 
studies in public health policy and planning (Engels et al., 2010; NCI, 2010). 
The reliability of the data from the SEER database has been previously reported 
(Abel, 2011; Engels et al., 2010).  The SEER-Medicare data have been used in over 900 
previously published studies evaluating cancer patterns of care, quality of care, cost of 
treatment, and cancer disparities (NCI, 2010).  This NCI and CMS supported database is 
one the largest and most comprehensive epidemiologic surveillance cancer databases that 
contain over 1.6 million cancer patients.  Maintaining the quality of the SEER data for 
completeness and quality has been ongoing since the database was initiated in the 1970’s 
(Clegg et al., 2007).  As well the SEER-Medicare database is updated biennially (Engels 
et al., 2010).  Utilizing a large population database like the SEER-Medicare database 
allows for tracking cancer overtime.   
This study assessed the association between race/ethnicity and first line NSCLC 
treatment and treatment according to the clinical practice guidelines; therefore, it was not 
be possible to establish causation.  Internal validity for a correlation study will be weaker 
than for an experimental deign study.  As with any retrospective study, data may be 
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incomplete or inaccurate.  For example, there may be limited or missing data on the use 
of tobacco, performance status, or co-morbidities (Engels et al., 2010).  Data regarding 
age, date of diagnosis, stage of disease, and cancer histology in the SEER database were 
found to be fairly accurate (Field, Smith & Lynch, 2004; Field et al., 2004).  Utilizing the 
SEER-Medicare database only allowed for generalization to the elderly population aged 
65 years and older with NSCLC.   
Ethical Procedures 
 Protecting patient information is of paramount importance with this study.  An 
informed consent from the patient was not required for this research study; however, all 
reasonable measures were taken to protect the SEER-Medicare data. The database was on 
a device that is password protected. To protect patient anonymity, certain data within the 
SEER-Medicare database were restricted and not included as part of the files.  These 
variables include patient census track zip codes and the zip codes for physicians and 
hospitals (SEER-Medicare, 2014).  In addition, the hospital and physician name were 
encrypted.  The NCI and Walden University requirements regarding the protection of 
patients, healthcare facilities, and providers were followed. The NCI requirements 
regarding cell sizes were followed when conducting statistical analyses to prevent the 
potential identification of patients.  All files received from the NCI, SEER-Medicare 
database for this research will be destroyed at the completion of the study as required by 
the NCI and the NCI will be notified of destruction.  As noted previously, approval from 
the IRB at Walden University was necessary prior to requesting data from SEER.  IRB 
approval # 06-05-15-0174312 was granted.  Approval by the SEER managers prior to 
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initiating the data analysis was also necessary.  A copy of the Data Use Agreement 
(DUA) and the approval letter to use the SEER-Medicare database is provided in the 
appendix (Appendix A).  There are no conflicts of interest. 
Summary 
 In summary, this quantitative retrospective study using the NCI SEER database 
linked to the Medicare insurance database between 2009-2013 was conducted to answer 
the question of the likelihood of being treated according to the NCCN treatment 
guidelines in the first line setting taking into consideration race/ethnicity, age, gender, 
stage of disease and histology.  In the presence of clinical practice guidelines it is unclear 
if disparities exist when treating NSCLC patients.  Chapter 3 described the methodology 
for this research study, including the overall study design, study population, sampling 
techniques, data collection, and ethical considerations.  Data analysis and issues 
pertaining to reliability and validity of the SEER-Medicare database were also addressed.  
Chapter 4 summarizes the data based upon the statistical analyses described in this 
chapter.  Chapter 5 provides a summary and interpretation of the study results and 




Chapter 4: Results  
Introduction 
 The purpose of this retrospective population-based cohort study was to evaluate 
the relationship between Caucasian, African American, and Hispanic race/ethnicity, as 
stratified by histology (squamous vs. adenocarcinoma), and stage of disease (stage IIIB or 
IV) to the receipt of first-line treatment for NSCLC). To understand the differences in 
treatment of first-line NSCLC by race/ethnicity, an evaluation of NSCLC patients aged 
65 years and older was conducted using the NCI’s SEER-Medicare linked database. 
SEER is the most comprehensive clinical database for cancer research and includes 
patients’ demographic, clinical, and treatment information. SEER also provides 
information on patients from across the United States receiving treatment in different 
treatment centers, both community and academic centers, which makes the analysis more 
representative of the total cancer patient population. The SEER database linked with the 
Medicare database combines the patient clinical information with insurance claims and is 
also the only source of population-based information in the United States that includes 
stage of cancer at the time of diagnosis. The SEER-Medicare database allows for the 
longitudinal study of patients 65 years and older over the course of their diagnosis and 
treatment. The database also provides the power to evaluate regional treatment and 
disparities among race/ethnicity.  
 The results of the data analysis in Chapter 4 are presented in tables to describe the 
findings of the study. The demographic variables (age, gender, and geographic location) 
were cross-tabulated by ethnic groups (Caucasians, African Americans, and Hispanics) 
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for comparison. Descriptive statistics are shown based on each of the racial/ethnic groups 
studied. Stage of disease and histology were considered possible confounding variables. 
The results from the logistic regression analyses are described and organized by ethnicity 
to provide comparisons for stage and histology. 
 The research question and hypotheses that were studied are as follows: 
What is the likelihood of Caucasian, African American, and Hispanic patients 
with NSCLC are being treated equally according to the National Comprehensive Cancer 
Network (NCCN) practice guidelines within stage and histology strata after controlling 
for age, gender, and geographic location?  
H01: Caucasian and African American patients with NSCLC are equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology 
strata after controlling for age, gender, and geographic location. 
H11: Caucasian and African American patients with NSCLC are not equally likely to 
be treated according to the NCCN treatment guidelines within stage and histology 
after controlling for age, gender, and geographic location. 
H02: Caucasian and Hispanic patients with NSCLC are equally likely to be treated 
according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age, gender, and geographic location. 
H12: Caucasian and Hispanic patients with NSCLC are not equally likely to be treated 
according to the NCCN treatment guidelines within stage and histology strata 
after controlling for age, gender, and geographic location. 
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Ho3: Hispanic and African American patients with NSCLC are equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology 
strata after controlling for age, gender, and geographic location.    
H13:  Hispanic and African American patients with NSCLC are not equally likely to be 
treated according to the NCCN treatment guidelines within stage and histology 
strata after controlling for age, gender, and geographic location. 
This chapter details the data collection methods and the quantitative analysis 
conducted. Under the research question the patient characteristics and the results are 
described.  A logistic regression analysis was conducted and the results were related to 
the research question. Baseline descriptive statistics were also reviewed. The chapter 
concludes with a summary section that provides answers to the research questions and 
then transitions to Chapter 5. 
Data Collection 
 For this study, I used a secondary analysis of data obtained from the NCI-SEER 
database. After Walden University’s Institutional Review Board (IRB) approved the 
research, a proposal was submitted to the NCI to obtain the SEER-Medicare data for 
patients with lung cancer. After approving the proposal, the NCI provided a DVD with 
the SEER and Medicare claims data sets for lung cancer for the years 2009 through 2013 
for analysis. The data on the DVD were uploaded onto an external server where the data 
were analyzed and stored for the duration of the analysis. The data were prepared and 
analyzed using IBM-SPSS 23.0. 
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 The SEER-Medicare database contained data on patients diagnosed with lung 
cancer between 2009 and 2013. The inclusion criteria for the cases included having 
tumors of the lung and bronchus as well as being at least 65 years of age at diagnosis. 
Individual data for each case were collected included ethnicity age, gender, geographic 
location, stage of disease (stage IIIB or IV), histology, and treatment. The independent 
variables in this study were age, gender, stage of disease, histology, and geographic 
location. The dichotomized response variable in the logistic regression model was 
whether the treatment provided was in accordance with the NCCN treatment guidelines.  
The initial sample size was 77,367 cases with 12,341 cases used in the logistic regression 
model. Patients were excluded if they had stage I, II, or IIIA NSCLC, if they had a 
previous or concurrent cancer other than basal cell carcinoma, had a lung cancer 
histology other than adenocarcinoma or squamous cell carcinoma, were not enrolled in 
Medicare Part A and Part B at the time of diagnosis, or were enrolled in Medicare as a 
result of end-stage renal disease or disability and were less than 65 years of age.  As a 
result of these exclusion criteria, 14,882 cases were available for analysis. These cases 
were then matched with their Medicare records and an additional 2,541 patients were 
unable to be matched with Medicare claims, resulting in a final number of 12,341 







Total number of SEER patients with a diagnosis of NSCLC 
N= 77,367 
Exclude patients diagnosed stage with stage I, II, IIIA NSCLC 
N= 34,050 
Exclude patients with a diagnosis of small cell lung cancer 
N= 6,943 
Exclude patients with histology other than adenocarcinoma or squamous cell carcinoma 
N= 8,441 
Exclude patients with previous or concurrent cancer excluding basal cell carcinoma of skin 
N= 4,537 
 
Exclude patients younger than 65 years of age at diagnosis 
N= 4, 123 
Exclude patients enrolled in Medicare with end stage renal disease 
N= 2348 
Exclude patients not enrolled in Part A and B Medicare 
N= 927 
Patients unable to be matched with Medicare claims 
N= 2,541 
 
Final number of patients included in study cohort 
N= 12, 341 
Figure 4.  Flow diagram showing patient selection process 
 The final sample for this study included Caucasian, African American, and 
Hispanic patients with Medicare coverage who were at least 65 years of age, and had 
been diagnosed with stage IIIB or stage IV NSCLC. All patients had Part A and Part B 
Medicare coverage at the time of diagnosis and continuously during their treatment.  
The SEER-Medicare linked data set represents the 18 SEER registry areas only 
and therefore only approximately represents the general population. Patients from the 
SEER registry may not be representative of the general population in the United States 
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diagnosed with NSCLC as some patient groups were underrepresented, such as African 
Americans and Hispanics. Age and gender in the SEER-Medicare dataset generally are 
representative of the general population.   
Results 
Descriptive Statistics 
 The final number of patients who met the inclusion and exclusion criteria for the 
study in these analyses was 12,341.  The demographic variables were summarized by 
race/ethnicity using frequency distributions.  The results of this analysis are presented in 
Table 2.  The largest percent of patients (n = 2,929, 23.7%) were between 70 and 74 
years of age, with those diagnosed at 85 years and older (n = 1,533, 14.5%) representing 
the smallest group. There were slightly more male patients (n = 6,630, 53.7%), than 
female patients (n = 5,711, 46.3%) included in the analysis. Most patients included in the 
study were Caucasian (10,940, 88.6%), with 1,245 (10.1%) African American, and 156 
(1.3%) Hispanic. The majority of the patients (72.3%) had stage IV metastatic disease 
and 27.5% had stage IIIB disease. There were 3,398 patients (27.5%) presenting with 
stage IIIB disease. The histology with the largest number of participants was 
adenocarcinoma (72.3%), while 27.7% had squamous cell.  Geographically the largest 
percent of patients were from the West (37.6%), and lowest percent was in the Midwest 
(13.4%).  
 Within race/ethnicity patient characteristics were fairly well balanced for 
squamous cell histology, stage, and gender (table 2).  Across race/ethnicity for 
geographic location, 81.4% of Hispanics lived in the West compared to 39.0% of 
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Caucasians and 20.6% of African Americans.  Forty-five percent of African Americans 
lived in the South, compared with 27.1% of Caucasians and 3.2% of Hispanics.  There 
were no Hispanics in the Midwest region.  For age at diagnosis, race/ethnicity was fairly 
well balanced for ages 65-69 and 70-74 years.  Nearly one-quarter of African-Americans 
(23.8%) were aged 75-79 years, closely followed by Caucasians (23.1%) and lastly, 
Hispanics (10.9%).  Hispanics were generally older than other racial/ethnic groups. 
Nearly one-third of Hispanics (32.1%) were age 80-84 followed by nearly 20% of 
Caucasians (19.4%) and lastly African Americans (14.2%). For patients age 85 and older 






Clinical and Demographic Characteristics by Race/Ethnicity (N=12,341) 
 
Characteristics Caucasian 





Age at Diagnosis, N (%)    
     65-69 2322 (21.2) 335 (26.9) 32 (20.5) 
     







     







     







      







    
Gender, N (%)    
     Male 5822 (53.2) 710 (57.0) 98 (62.8) 
     







    
Stage, N (%)    
         IIIB  3005 (27.5) 356 (28.6) 37 (23.7) 
     








    
Histology    
     Adenocarcinoma 7944 (72.6) 869 (69.8) 115 (37.7) 
      









   
     Northeast 2256 (20.6) 226 (18.2) 24 (15.4) 
      







      







      










 Patient treatment in accordance to NCCN treatment guidelines was cross- 
tabulated by race/ethnicity.  An analysis was also cross-tabulated by gender, age, stage of 
disease, and geographic location within race/ethnicity and these analyses are presented in 
Tables 4-8.  The total number of participants’ treated according to NCCN guidelines by 
race/ethnicity are shown in Table 3. 
 
Table 3 
 Treatment According to NCCN Guidelines by Race/Ethnicity (N = 12, 341) 
 
 





Ethnicity Caucasian African American Hispanic 
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  A total of 10,940 Caucasians were included in the analysis, of which 858 (7.9%) were 
treated according to the NCCN guidelines, followed by 78 African Americans (6.3%), 










Treatment According to NCCN Guidelines by Stage of Disease and Race/Ethnicity  

























      
      
      










   2,953  (86.9) 
      






  856 (96.3) 
 
 114 (95.8) 
 
 8,445  (94.4) 
 
  When evaluating stage of disease (Table 4), there were fewer patients with stage 
IIIB disease than stage IV disease.  Of the total 3,398 patients with stage IIIB disease, 
445 patients (13.1%) were treated according to the NCCN guidelines, including 13.2% of 
Caucasians followed by African Americans (12.6%) and Hispanic patients (5.4%).  Of 
the total 8,943 patients with stage IV disease, 498 (5.6%) were treated according to the 
guidelines.  There were 460 Caucasian patients (5.8%) with stage IV disease treated 
according to the guidelines, 5 Hispanic patients (4.2%), and 33 African Americans (3.7) 



















     
Adenocarcinoma     
     Yes 560 (7.0) 55 (6.3) 5 (4.3) 620  
     
      No 7384 (93.0) 814 (93.7) 110 (95.5) 8308 
     
     
Squamous     
     Yes 298 (9.9) 23 (6.1) 2 (4.9) 323  
     
     No 2698 (90.1) 353 (93.9) 39 (95.1) 3090 
     
 
 For histology (Table 5), there were a total of 3,413 patients diagnosed with 
squamous cell lung cancer, with 323 (9.5%) receiving treatment according to NCCN 
guidelines.  Among the total 8,928 patients who had adenocarcinoma, 620 (6.9 %) were 
receiving treatment according to NCCN guidelines.  Seven percent of Caucasians with 
adenocarcinoma were treated according to the guidelines, followed by African Americans 
(6.3%), and Hispanics (4.3%).  Approximately 10% of Caucasians with squamous cell 
carcinoma were treated according to the guidelines (9.9%), followed by African 


























 n (%) 
      
    65-69 Yes 258 (11.1) 32 (9.6) 3 (9.4) 293 (10.9)  
      
      
     70-74 Yes 233 (9.1) 17 (5.1) 1 (4.0) 251 (8.6)  
      
      
     75-79 Yes 214 (8.5) 21 (7.1) 0 (0) 235 (8.3)  
      
      
     80-84 Yes 115 (5.4) 8 (4.5) 3 (6.0) 126 (5.4)  
      
      
     85 + Yes 38 (2.7) 0 (0) 0 (0)  38 (2.5) 
 
 Table 6 shows the number and percent of patients in each age group by 
race/ethnicity treated according to the guidelines as a percent of the total number of 
patients for the age group.  There were a total 2,686 patients in the age group 65-69 of 
which 10.9% were treated according to the NCCN guidelines.   Eleven percent of 
Caucasians in the 65-69 year age group were treated according to the guidelines, 
followed by 9.6% of African Americans, and 9.4% of Hispanics.  For patients aged 70-74 
years, a total of 251 patients (8.6%) were treated according to the guidelines, including 
9.1% of Caucasians, 5.1 % of African American patients, and 4.0 % of Hispanics.  A total 
of 235 patients (8.3%) aged 75-79 treated according to the NCCN guidelines.  There were 
214 Caucasian patients (8.5%) and 21 (7.1%) African Americans treated appropriately.  
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There were no Hispanic patients in the 75-79 aged group treated according to guidelines.  
In the 80-84 year aged group there were a total of 126 patients (5.4%) treated according 
to guidelines; 5.4% of Caucasians, 6.0% of Hispanics, and 4.5% of African American. 
The lowest percent of patients treated according to the guidelines were in the 85 and 
older age group (2.5%) and were all Caucasians.   
 
Table 7 
Treatment According to NCCN Guidelines by Gender (N = 12, 341) 




































      
Female Yes 382 (7.5) 26 (4.9) 1 (1.7) 409 (7.2) 
 
 Table 7 represents the percentage of male and female patients treated according to 
the guidelines with each race/ethnic group.  Of the total 6, 630 males, 534 (8.1%) were 
treated in accordance with the NCCN guidelines and of the total 5,711 females 409 
(7.2%) were treated according to the guidelines.  Within each racial/ethnic group a lower 
percentage of females than males received guideline appropriate treatment. There were 
382 (7.5%) female Caucasian patients who received guideline appropriate treatment 
followed by 26 (4.9%) female African American patients, and 1 (1.7%) female Hispanic 
patient that received treatment according to the guidelines.  In comparison, 8.2% 
Caucasian males were treated according to the guidelines followed by 7.3% of African 
91 
 




Treatment According to NCCN Guidelines by Region and Race/Ethnicity (N= 12, 234) 
Geographic 
region 



























 Midwest Yes 134 (9.2) 8 (4.0) 0 (0) 142 (8.6) 
      
  South Yes 242 (8.2) 41 (7.3) 0 (0) 283 (8.0) 
      
  West Yes 299 (7.0) 15 (5.9) 6 (4.7) 320  (6.9) 
 
 Table 8 shows the percent of patients by region within each racial/ethnic group 
who were treated according to the NCCN guidelines as a percent of the total number of 
patients in each region.  There were a total of 198 (7.9%) patients in the Northeast, 142 
(8.6%) patients in the Midwest, 282 (8.0%) patients in the South, and 320 (6.9%) patients 
in the West received treatment according to the guidelines.  Across all regions a larger 
percent of Caucasians received appropriate treatment to the guidelines as compared to 
African American and Hispanic patients.   There were no Hispanic patients in the 
Midwest or South that received treatment according to the NCCN guideline. 
Logistic Regression Overview 
 A regression analysis was conducted that included all independent and covariate 
variables entered simultaneously into the analysis (Table 9).  The dependent variable was 
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treatment according to the NCCN guidelines.  The full regression model reveals there 
was a significant difference between African Americans compared to Caucasians treated 
according to the guidelines OR= .68[95% CI (.54, .88, p= .002)].  There was a 32% 
decrease in the odds of African Americans being treated according to the guidelines.    
There was not a statistically significant difference between Caucasians and Hispanics (p= 
.373). The results of the full model show that as age increased the odds of being treated in 
accordance to the guidelines decreased. The results of the full model show that age at 
diagnosis was statistically significant for all age groups and had a negative correlation to 
treatment.  Results revealed that gender was not significant predictor OR = .92 (95% CI 
[.80, 1.0, p = .210]).   
 Geographic region was associated with receiving treatment according the NCCN 
guidelines; patients living in the West had lower odds OR = 0.82, (95% CI [.68, .99, p = 
.036]) of receiving treatment according to NCCN guidelines as compared to patients in 
the Northeast.   The results of each logistic regression model are presented by and 
categorized by stage of disease and histology (e.g., stage IIIB adenosquamous, stage IV 
adenocarcinoma, stage IV squamous cell) with comparisons by race/ethnicity, Caucasian 
compared to African American and Hispanics and African Americans compared to 








Full Logistic Regression with all Variables and Covariates for Treatment According to 
the NCCN Guidelines 
 





    
 70-74 
 
-.28 9.47 .75 .63 .90 .002 
 75-79 
 
-.36 15.22 .70 .58 .83 <.000 
 80-84 
 
-.88 59.63 .42 .34 .52 <.000 


































-.35 .79 .70 .33 1.53 .373 
Geographic Location   6.77     
  















-.10 1.10 .90 .74 1.10 .295 
 West 
 
-.20 4.41 .82 .68 .99 .036 
Squamous cell 
 
.27 9.31 1.25 1.08 1.45 .002 




Research Question and Hypotheses  
 In the sections that follow, pair wise comparisons for the racial/ethnic groups 
within strata defined by stage of disease and histology are provided.   
Caucasians Compared to African Americans 
 The first pair wise comparison was between Caucasians and African Americans.   
Stage IIIB Adenosquamous Carcinoma 
 Of the 3398 patients with stage IIIB NSCLC, 2,953 patients were not treated 
according to the NCCN guidelines, and 455 patients were treated according to the NCCN 
guidelines included in this model.   
 There was not a significant difference between Caucasians and African American 
patients treated per the guidelines OR= .812 (95% CI [.58, 1.137, p= .225]). The odds of 
females being treated according to the guidelines were not significantly different from 
males, OR = .93 (95% CI [.76, 1.14, p = .478]).  The odds were less that patients age 85 
and older were treated according to the guidelines (OR= .225, [95% CI .14, .35, p= 
0.000]), when compared to patients’ aged 65 to 69.  Patients living in the West had 30% 
lower odds of receiving treatment according to the guidelines when compared with those 
in the Northeast OR= .699 (95% CI [.51, .90, p= .008]).  Patients in the Midwest had 
23% higher odds of not being treated according to NCCN guidelines OR=1.23 (95% CI 






Results of Logistic Regression of Caucasian Patients Compared to African American 
Patients within Stage IIIB Adenosquamous Carcinoma  
 
 
 Wald OR CI lower CI upper p-value 
Age Group      
 65-69  
 
55.38     
 70-74 
 
2.62 .79 .59 1.05 .106 
 75-79 
 
1.89 .82 .62 1.09 .169 
 80-84 
 
21.02 .47 .34 .65 .000 
 85+ 42.08 .22 .14 .35 .000 
 
Geographic Region 
     
 Northeast 
 
18.12     
 Midwest 
 
2.07 1.23 .917 1.78 .150 
 South .108 .95 .715 1.27 .743 
  












Race/Ethnicity      
 Caucasian 
 
2.186     
 African American 1.47 .812 .58 1.137 .225 
        
Gender 
 
     
 Female .50 .93 .76 1.14 .478  
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Stage IV Adenocarcinoma 
 Table 11 presents results for Caucasian patients compared with African American 
patients with stage IV adenocarcinoma.  There were 386 patients treated according to the 
NCCN guidelines and 6,263 patients were not treated according to the guidelines.  
 A comparison of Caucasian and African Americans with stage IV 
adenocarcinoma revealed race/ethnicity was statistically significant for predicting 
treatment OR = 625(95% CI [.417,938 p= .023]). The odds of African Americans with 
stage IV adenocarcinoma being treated according to the guidelines decreased by nearly 
38% OR= .625, (95% CI [.47, .938 p= .023).  Age at diagnosis within all age groups was 
statistically significant for treatment according to the guidelines.  As age increased, the 
odds of treatment according to the guidelines decreased for all age groups as compared to 
patients 65-69 years of age. Geographic location and gender were not significant 





Logistic Regression in Caucasian Patients Compared to African American Patients with  
Stage IV Adenocarinoma  
 
 
 Wald OR CI lower CI upper p value 
Age Group      
 Age 65-69 64.81     
 Age 70-74 
 
8.88 .67 .52 .87 .003 
 Age 75-79 
 
15.02 .58 .44 .76 .000 
 Age 80-84 
 
30.97 .38 .27 .53 .000 
 Age 85+ 38.92 .10 .05 .21 .000 
 
Gender 
     
 Female 1.09 .90 .73 1.10 .296 
 
Race/Ethnicity 
     
    Caucasian 
 
5.85     
African American 5.16 .625 .417 .938 .023 
    
Geographic Location 
     
 Northeast 
 
     
 Midwest 
 
.02 1.03 .71 1.49 .886 
 South 
 
.05 .97 .71 1.31 .828 
 West .08 1.04 .79 1.38 .775 
 
 
Stage IV Squamous Cell Carcinoma 
 
 Results of the pair wise analysis with Caucasian patients compared to African 
American patients with stage IV squamous cell carcinoma are shown in Table 12. Of the 
2,294 patients with stage IV squamous cell carcinoma, 112 patients received treatment 
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according to the NCCN guidelines and 2, 182 patients did not receive treatment 
according to the NCCN guidelines.   
 Race/ethnicity overall was significant for treatment between Caucasians and 
African Americans according to the guidelines in patients with stage IV squamous 
carcinoma of the lung.  African Americans had a nearly 59% lower odds of being treated 
according to NCCN guidelines when compared to Caucasians, OR = .413 (95% CI [.178, 
.957 p= .039]).  Age at diagnosis was statistically significant in predicting treatment 
according to NCCN guidelines for the age groups 80 to 84 OR = .44 [95% CI (.221, .876 
p= 0.19)] and 85 years and older OR= .304 [95% CI (.12, .80. p= .016)] were the only 
age groups that were statistically significant.  These two age groups had lower odds of 
being treated according to the guidelines than patients’ age 65 to 69. Patients’ age 70 to 
74 had a 12% higher odds of receiving treatment according to the guidelines although this 





Logistic Regression for Caucasian vs. African American Patients with Stage IV  
Squamous Cell Carcinoma  
 
 





    
 
  
     Age 65-69 
 
13.56 
    
  
     Age 70-74 
.205  1.12 .68 1.85 .650 
  
     Age 75-79 
.58 .81 .42 1.39 .448 
  
     Age 80-84 
5.46 .44 .22 .88 .019 
  
     Age 85+ 
5.84 .30 .12 .80 .016 
 
Gender 
     
  
      Female 
1.19 .80 .53 1.20 .276 
 
Geographic Location 
     
 Northeast 
 
4.70     
 Midwest 
 
3.56 .52 .26 1.03 .059 
 South 
 
2.14 .68 .41 1.14 .144 
 West 3.08 .62 .37 1.06 .079 
 
Race/Ethnicity 
     
     Caucasian 
 
4.53     
      African  
     American 
    





Comparison of Caucasians and Hispanics 
 The second hypothesis was to determine if Caucasian and Hispanic patients with 
NSCLC were equally likely to be treated in accordance with the NCCN treatment 
guidelines within stage and histology strata.  The pair wise comparisons are shown in 
Tables 13-15.  
Stage IIIB Adenosquamous Carcinoma 
 Among patients with Stage IIIB adenosquamous carcinoma, 445 were treated 
according to the NCCN guidelines and 2,953 patients were not treated using these 
guidelines. The results are in Table 13. 
 Race/ethnicity was not a significant contributor in predicting treatment according 
to the guidelines.  A non-statistical difference was found in the odds of being treated in 
accordance to the guidelines for Caucasians as compared to Hispanics OR = .93 (95% CI 
[.62, 1.39, p =0.38]).  However, these results should be interpreted with caution due to the 
small number of Hispanics patients compared to Caucasian patients. 
  Age at diagnosis was significant in predicting treatment per the NCCN 
guidelines. Patients in age group 80 to 84 had a 53% lower odds of being treated 
according to the guidelines as compared to patients aged 65-69 OR = .47 (95% CI [.34, 
.65, p = .000]).  Patients age 85 and over had 73% lower odds of receiving treatment 
according to the guidelines as compared to patients age 65-69.  However, because of the 
small sample size, caution should be taken when interpreting these results. 
 Geographic location was statistically significant in this model for patients living 
in the West.  For patients in the West, odds of being treated according to the guidelines 
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was 31% lower than patients living in the Northeast, OR = .69 [95% CI (.51, .90, p = 
.008)].    
Table 13 
 
Logistic Regression for Hispanic Patients Compared with Caucasian Patients with Stage  
IIIB Adenosquamous  
 
 
Patient Characteristic Wald OR CI lower CI upper p value 
Age Group      
 Age 65-69 55.38     
 Age 70-74 
 
2.62 .79 .59 1.05 .106 
 Age 75-79 
 
1.89 .82 .62 1.09 .169 
 Age 80-84 
 
21.02 .47 .34 .65 .000 
 Age 85+ 42.08 .23 .14 .35 .000 
 
Gender 
     
 Female 
 
.50 .93 .76 1.14 .478 
Race/Ethnicity      
 Caucasian .744 .93 .62 1.39 .38 
 Hispanic 
 
2.19     
 
Geographic Location 
     
 Northeast 
 
18.12     
 Midwest 
 
2.07 1.28 .92 1.78 .150 
 South 
 
.11 .95 .72 1.27 .743 
 West 6.99 .68 .51 .90 .008 
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Stage IV Adenocarcinoma 
 A pair wise test comparing Caucasians and Hispanics being equally treated 
according to the NCCN guidelines are shown in Table 14.  Included in this analysis were 
386 patients who were treated according to the NCCN guidelines and 6,263 patients who 
did not receive treatment according to the NCCN guidelines.   
 Race/ethnicity, gender, and geographic location were not significant predictors of 
treatment to the guidelines.  A significant difference in the odds was not found for 
Hispanics and Caucasian patients with stage IV adenocarcinoma OR= 1.68 (95% CI 
(.523, 5.41, p = .383)].  This result may be due to the small number of Hispanic patients 
in the cohort. Because few Hispanics with stage IV adenocarcinoma were included in this 
model compared to Caucasians, drawing conclusions is difficult. 
 Age at diagnosis for all age groups was the only variable that was statistically 
significant in predicting treatment in accordance to NCCN guidelines in patients with 
stage IV adenocarcinoma compared to patients age 65-69.  Patients age 85 and older had 
the lowest odds of being treated according to the guidelines as compared to patients age 
65 to 69 OR = .10 [95% CI (.05, .21, p = .000)].  As age increased, the odds of treatment 








Logistic Regression for Hispanic Patients Compared to Caucasian Patients with Stage IV 
Adenocarcinoma  
 
Patient Characteristic Wald OR CI lower CI upper p value 
Age Group      
 Age 65-69 
 
64.81     
 Age 70-74 
 
8.88 .67 .52 .87 .003 
 Age 75-79 
 
15.02 .58 .44 .76 .000 
 Age 80-84 
 
30.96 .38 .37 .53 .000 
 Age 85+ 38.92 .10 .05 .21 .000 
Gender      
 Female 
 
1.09 .90 .72 1.10 .296 
Race/Ethnicity      
 Caucasian .76 1.68 .52 5.41 .38 
     Hispanic 
 






    
 Northeast 
 
.338     
 Midwest 
 
.020 1.03 .71 1.49 .886 
 South .047 .97 .71 1.31 .828 
  



























Comparison of Hispanics and African Americans 
 The pair wise comparison for Hispanic and African American patients with 
squamous cell carcinoma is shown in Table 15.  Because Hispanics  (n=33) are a smaller 
group in this study than African Americans (n= 255), the analysis was conducted with 
Hispanics as the reference group. Results of the analysis revealed a non-statistical 
difference in treatment between Hispanics and African American patients OR = .29 [95% 
CI [(.05, 1.54, p = .145)]. Because of the small number of Hispanic patients with stage IV 
squamous cell lung cancer, drawing any conclusions regarding treatment comparisons in 
accordance to the guidelines is difficult. 
 Age at diagnosis in all age groups was the only significant predictor for treatment 
in accordance in NCCN guidelines and indicated that as age increased the odds of being 
treated according to NCCN guidelines decreased.  Only patients in the West showed a 
significant difference in treatment according to the guidelines OR = (95% CI [.67, .98, p= 
0.04]).   
 The comparison of Hispanic and African American patients with stage IV 
adenocarcinoma, revealed there was not a statistical difference in the odds of treatment 
OR=1.05 (95% CI [.307, 3.59, p=. 936]) and that both groups were closely treated to the 
guidelines.  However, due to the small sample size conclusions cannot be drawn 





Logistic Regression of Hispanic Patients Compared to African American Patients with  
Stage IV Squamous Cell Carcinoma   
 
 
 Patient Characteristics Wald OR CI lower CI upper p value 
      
Age      
 Age 65-69 
 
128.5     
 Age 70-74 
 
9.4 .75 .63 .90 .00 
 Age 75-79 
 
15.21 .67 .58 .83 .00 
 Age 80-84 
 
59.63 .42 .38 .52 .00 
 Age 85+ 
 
92.26 .13 .13 .26 .00 
Gender      
 Female 
 
1.57 .91 .80 1.05 .21 
Race/Ethnicity      
 Hispanic 
 




2.12 .287 .053 1.53 .14 
Geographic Location      
 Northeast 
 
6.76     
 Midwest 
 
.66 1.030 .81 1.29 .79 
 South 
 
1.97 .90 .74 1.09 .29 





Post Hoc Analysis 
 Because the number of African American and Hispanic patients individually was 
small, their numbers were combined and a new racial/ethnic group was created and titled 
other race/ethnicity.  The other race/ethnicity group contains 1401 patients. 
  A post hoc full model regression analysis was performed (Table 16).  The results 
showed the odds of patients in the other race/ethnicity were less likely to be treated 
according the to guidelines than Caucasians.  There was a 31% reduction in the odds of 
being treated according to the guidelines OR= 0.69, (95% CI [.534, .869, p= .002]).  Age 
at diagnosis was significant in all age groups.  As age increased, the odds of treatment 
according to the NCCN guidelines were less likely. Gender is not statistically 
significantly associated with treatment according to the NCCN guidelines in the post hoc 
analysis. There was a statistically significant difference in treatment between patients in 
the West as compared to patients in the Northeast OR= .818 (95% CI [.678, .987, p= 





















Age at Diagnosis 
     
      
     65-69 
 
128.660 
    
      











      











      











      











Gender      
     Female 1.57 .916 .799 1.050 .209 
Race/Ethnicity      
      











Region      
     
     Northeast 
 
6.782 
    
    











     South 1.104 .90 .742 1.094 0.30 
    West 4.408 .818 .678 .987 .036 
Stage      
      











Histology      
      















 The purpose of this population-based cohort study was to determine the likelihood 
of elderly patients with stage IIIB or IV NSCLC adenocarcinoma or  
squamous cell carcinoma being equally treated according to the NCCN guidelines. For all 
research hypotheses, a binary logistic regression model was conducted controlling for 
covariates. Overall, the odds of treatment according to the NCCN guidelines was poor 
with 92.4% of patients not likely to receive treatment according to the guidelines and 
7.6% of patients likely to receive treatment according to the guidelines. The results were 
mixed for the likelihood of being equally treated according to the guidelines for 
race/ethnicity.  
 The first hypothesis tested that Caucasians and African Americans with stage IIIB 
adenosquamous carcinoma were equally likely to the treated according to NCCN 
guideline was not retained.  For Caucasian and African American patients with stage IV 
adenocarcinoma and stage IV squamous cell carcinoma, the null hypothesis (H0) was 
rejected. Caucasian and African American patients were not equally treated according to 
the guidelines.  The odds of African American patients being treated in accordance to the 
guidelines was less than for Caucasians. 
 The odds of Caucasian and Hispanic patients being equally treated according to 
the NCCN guidelines revealed no statistically significant difference; therefore, the null 
hypothesis was retained.  However, caution should be taken when evaluating the data, 
due to the small number of Hispanic patients in this cohort.    
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 The odds of Hispanics and African Americans being equally treated according to 
NCCN guidelines indicated they were equally likely to be treated according to the 
guidelines while controlling for other variables. When other factors that could affect 
treatment were considered, age at diagnosis was significant in all analyses, revealing that 
older patients were less likely to be treated according to the NCCN guidelines when 
compared to patients age 65-69.  No differences were found in the odds of treatment 
according to NCCN guidelines between males and females within stage and histology for 
all models.   
 For all patient groups, patients with adenocarcinoma were less likely to receive 
treatment according to the guidelines as compared to patients with squamous cell 
carcinoma.  Stage IV patients were less likely to be treated according to the guidelines 
than Stage III patients.  In a post hoc analysis, when African American and Hispanic 
patients were combined to create a new race/ethnicity category, other races, there was a 
statistical difference between Caucasians and other races in treatment according to the 
NCCN guidelines, therefore the null hypothesis was not retained.  Chapter 5 discusses the 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
 The purpose of this population-based cohort study was to evaluate if patients age 
65 years or older with stage IIIB or stage IV adenocarcinoma or squamous cell histology 
NSCLC were equally treated according to the NCCN guidelines. Specifically, this 
research was undertaken because few studies on cancer, including lung cancer, have 
looked at treatment adherence based on national clinical guidelines.  National guidelines 
for specific patient diagnoses are used to provide patient treatment recommendations 
based on efficacy, toxicity, and then cost when efficacy and toxicity are equal.  Failure to 
comply with the NCCN guidelines or other national guidelines for cancer treatment may 
compromise patient outcomes and increase the cost of care.  Based on the results of this 
study, race and age at diagnosis contributed to NSCLC treatment in accordance with the 
NCCN guidelines.  
Interpretation of Findings 
 The current analysis demonstrated that for patients with stage IV adenocarcinoma, 
the odds of African American patients being treated according to clinical guidelines were 
38% less than for Caucasians patients with the same diagnosis.  Among patients with 
stage IV squamous cell carcinoma, African American patients had 59% lower odds than 
Caucasian patients of being treated according to the NCCN guidelines.  In the post hoc, 
when race/ethnicity was evaluated, there was a 31% reduced chance of patients of other 
race/ethnicity being treated according to the guidelines compared to Caucasians.  Despite 
uniform health insurance coverage, the odds of being treated according to the clinical 
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guidelines vary.  The decision to treat elderly lung cancer patients is complex.  In this 
analysis, age at diagnosis was a significant factor for appropriate treatment.  There was an 
inverse relationship between age and treatment according to the guidelines.  These results 
are similar to the results from previous studies (Earle et al. 2000; Potosky et al., 2004).   
 Differences between Caucasian and African American patients with stage IIIB 
disease were not statistically significant; possibly due to the small probability that 
patients with stage IIIB cancer live longer than those with stage IV and can actually be 
cured in some cases with aggressive treatment (Simone, 2013). The lack of a significant 
difference between Caucasian and Hispanic patients, and between African American and 
Hispanic patients with stage IIIB or stage IV disease suggests that patients are equally 
likely to be treated according to the guidelines, and this is in agreement with previous 
studies (Goulart et al. 2012).  However, these results can be difficult to interpret, as the 
number of African American and Hispanic patients in this study was insufficient to 
predict a difference accurately.  The smaller number of Hispanic patients is a reflection of 
the lower incidence of smoking rates and lung cancer in Hispanic patients (Saeed et al., 
2012).  In addition, Hispanics with NSCLC tend to have more bronchiolalveolar 
histology than Caucasian or African American patients (Saeed et al. 2012).  
Bronchiolalveolar carcinoma, a subtype of adenocarcinoma of the lung, represents 
approximately 4% of NSCLC (Read, Page, Tierney, Piccirillo, & Govindan, 2004).  
Bronchioalveolar histology was not included in this study because most of these tumors 
are detected at an early stage and are usually resected (Maza, Meernik, Jeon & Cote, 
2015).   
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 Because little data is available on regional differences in the treatment of patients 
with cancer, I examined whether there were differences in adherence to NCCN treatment 
guidelines in NSCLC. This study revealed that patients with stage IIIB NSCLC living in 
the West were less likely to be treated according to the guidelines than patients in the 
Northeast. This difference may be due to more Hispanics living in the West as compared 
to the Northeast and regional differences among patients and physicians in beliefs 
regarding the treatment of advanced NSCLC.  Hirth et al. (2015) noted differences in 
treatment according to geographic location primarily between the Northeast and the West 
regions.  However, they found that these differences were poorly understood and might 
not be able to be generalized in all settings due to variations in barriers to using 
guidelines. A paucity of data is available about whether treatment is more aggressive in 
one region than another, or whether physician beliefs regarding lung cancer treatment 
differ across regions.  Regional differences in the adherence to guidelines for the 
treatment of prostate cancer, colon cancer, and rectal cancer were found in Texas, and the 
investigators found that the differences within the state may be due to some regions being 
more aggressive with treatment than other region.  Other reasons may be patient medical 
characteristics (Ho et al., 2016).  Makarov et al. (2012) found regional differences in 
cancer imaging among the SEER regions and that regions with high levels of appropriate 
imaging also had high levels of inappropriate imaging.  The reasons for these differences 
were poorly understood and may go beyond competition between health facilities 
(Makarov et al, 2015).  Understanding specific patterns of geographic variation may need 
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to be evaluated at the zip code, county, and hospital level and not the larger regional 
level, as in the present study. 
 Several studies have shown that factors associated with a variation in general 
cancer practice guideline compliance, including the NCCN guidelines, include (a) age, 
(b) comorbidities, (c) insurance type, (d) institution, (e) region, (f) lack of physician 
awareness of guidelines, (g) lack of physician agreement with guidelines, and (h) 
physician time and resources (Goldberg, Akard, Dugan, Faderl, & Pecora, 2015; Ho et 
al., 2016).  Ho et al. (2016) found that differences in the treatment of colon, prostate, and 
pancreatic cancer according to guidelines across Texas could be attributed to physician 
referral patterns, patient age, gender, being Black, and living in a lower income area. 
 The median age of patients in this analysis was 75-79, slightly older than patients 
diagnosed with lung cancer overall.  Data from the SEER database showed individuals 80 
years and older represent approximately 17% of lung cancer patients in the United States 
(Altundag et al., 2007; Chen et al., 2016; Owonikoto et al., 2007).  In this study, I found 
that age at diagnosis was a major contributor in determining treatment according to the 
NCCN guidelines.  Differences in treatments were observed between the patient age 
groups 75-79, 80-84, and over 85 years of age, as compared with patients 65-69 years for 
all groups.  As age increased, the odds of patients being treated according to the NCCN 
guidelines decreased, which was similar to findings reported in other studies (Boland et 
al. 2013; Wang et al, 2011). This difference may be due to the patient age, patient 
comorbidities, and/or treatment effects/toxicity.  Even with comorbidities, older patients 
were able to tolerate chemotherapy.  Chen et al (2016) found that 7.9% of octogenarians 
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received chemotherapy and Potosky et al. (2004) found that 21% of octogenarians with 
stage III NSCLC and 16% with stage IV NSCLC received recommended lung cancer 
treatment.  More recently, Cassidy et al. (2017) reported that patients with stage IIIB 
NSCLC, adenocarcinoma histology, advancing age, female gender, and who are Black 
received no treatment for their NSCLC.  Researchers at the Association of the British 
Pharmaceutical Industry (ABPI) have shown that a patient’s chronological age might 
differ from their biological age, which was based on an individual’s functional capacity, 
and could affect receipt of appropriate treatment (ABPI, 2012). Patient age was found to 
be a major influential factor in the decision of how physicians treated a patient, in 
addition to performance status (Foster et al., 2010).  A retrospective study from M. D. 
Anderson Cancer Center indicated that select patients with good performance status, 80 
years and older, were able to tolerate standard chemotherapy and outcomes were similar 
to younger patients (Altundag et al., 2007).  Because limited information is available 
from clinical trials on the use of cancer therapies in patients 70 years and older, further 
research is warranted.  
 Maintaining quality of life is an important consideration for patients receiving 
lung cancer treatment. Tradeoffs exist between side effects of treatment and clinical 
benefits.  These tradeoffs vary among patients depending on how they value time.  Some 
patients may prefer to avoid side effects, while other patients may consider side effects to 
be manageable and feel that benefits of treatment may offset the side effects.  Some 
patients may not want to receive aggressive treatment if the gain in life is not significant.  
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Quality of life for patients and the family should be considered and discussed with the 
physician. 
 Comorbidities, such as heart disease, diabetes, pulmonary diseases, hypertension, 
decreased renal function, alterations in drug metabolism, and “polypharmacy,” are 
common in elderly patients and can influence treatment decisions (Chen et al. 2016).  
Although elderly patients tend to have greater co-morbidity that contributes to increased 
toxicities, age alone should not prevent an elderly lung cancer patient from receiving 
treatment (NCCN Senior Adult Oncology, 2014; Tas, Ciftci, Kilic, & Karabulut, 2013; 
Wang et al, 2011).  Because the increased risk for toxicity from chemotherapy or 
radiation and co-morbidities decrease the likelihood of completing all treatment cycles, 
physicians might decide not to treat a patient according to clinical treatment guidelines 
(Chen et al., 2016). In some instances, the patient or family members may request 
treatment discontinuation.  The NCCN guidelines recommend physicians consider co-
morbidities when recommending cancer treatments for the elderly (NCCN Senior Adult 
Oncology, 2014).  Wang et al. (2011) found that when age and co-morbidity were both 
taken into account, elderly patients without co-morbidities were treated less frequently 
than younger patients with co-morbidities.  They also noted that patients over 85 were 
treated less frequently than patients 75 and younger (Wang et al, 2011). The NCCN 
clinical guidelines recommend single agent chemotherapy to improve quality of life and 
survival in patients 70 to 86 years of age (NCCN Senior Adult Oncology 2014; Tas et al., 
2013).  Doublet chemotherapy showed benefits in patients 70-80 years of age that were 
equivalent to patients younger than 70 years (Wang, Fuller, & Thomas, 2007).  While the 
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elderly cancer patient can be challenging to treat, they are also generally 
underrepresented in clinical trials due to strict exclusion criteria.  Therefore, additional 
clinical trials specific for the elderly cancer patient are warranted to determine optimal 
treatment (Tas et al., 2013).  
  Physician barriers to clinical practice guideline use in oncology have not been 
studied extensively (Goldberg et al., 2015).  Goldberg et al (2015) found resource 
barriers, lack of familiarity, and lack of agreement with the NCCN guidelines for Chronic 
Myelogenous Leukemia (CML) were reasons physicians did not following the guidelines.  
They found that 84% of physicians were familiar with the NCCN guidelines for CML, 
14% of physicians were familiar with the guidelines but did not use them in treating 
patients, and 2% of physicians were not familiar with the NCCN guidelines for CML 
(Goldberg et al., 2015).  Most physicians reported the guidelines were difficult to find, 
difficult to implement, offered few treatment options, and believed the guidelines 
hindered their autonomy to practice medicine (Greenberg et al. 2015).  A report by the 
New England Healthcare Institute (2008) revealed physicians were more likely to follow 
guidelines if they were relevant to their practice (NEHI, 2008).   
 Social cognitive theory was selected as the theoretical framework for this study as 
it focuses on individual cognitive influences and incorporates the adoption of evidence 
based practice changes. Lack of awareness and familiarity of guidelines can affect 
physician knowledge and decisions to use the guidelines (Cabana et al., 1999).  Fifty-six 
percent of physicians from a variety of specialties were unfamiliar with clinical 
guidelines and up to 91% did not agree with the guidelines.  Self-efficacy and expected 
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patient outcomes were found to be barriers to adopting treatment guidelines by physicians 
(Cabana et al., 1999).  Therefore, from a theoretical perspective, a lack of awareness and 
lack of familiarity may affect physician knowledge of the NCCN guidelines.   
Limitations of the Study 
 The SEER-Medicare linked data set is a large population-based database that 
collects data for evaluating cancer care in the elderly in 97% of the United States 
population 65 and older.  The Medicare database is an administrative database designed 
for tracking reimbursement claims.  However, the database has its limitations when 
applied for clinical research purposes, such as limited detailed diagnostic information, 
inconsistency in the use of procedural coding, and difficulty in determining the timing of 
events (Virnig & Madeira, 2012). The Medicare data are based on insurance claims data, 
are input from tumor registrars, and are subject to errors.  Because the SEER-Medicare 
linked database is a population-based database the data are not subject to selection bias or 
reporting bias. The limitations of the SEER-Medicare database relevant to this study are a 
lack of information regarding a patient’s performance status that is used to measure how 
a patients disease is progressing, treatment decisions, smoking status, patient co-
morbidities, weight loss, quality of life related to treatment, and reasons for not receiving 
treatment or refusal of treatment.  Because the population was limited to individuals with 
Medicare (age 65 or older) the findings may not be generalized to a younger population 
or patients with another type of insurance. As a retrospective study, an understanding of 
causality cannot be determined. 
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Recommendations for Future Research 
 By 2050 approximately 50% of the population is expected to be racial/ethnic 
minority, thereby increasing the potential for disparities in cancer care (Gorin, Badr, 
Krebs & Das, 2012). Although numerous studies have been conducted showing 
disparities in the treatment of cancer, including lung cancer, most of these studies have 
been in the earlier stages of the disease. Few studies, particularly in stage IIIB lung 
cancer have been published that evaluate healthcare disparities in the Hispanic 
population.  Lung cancer treatment is complex and overcoming healthcare disparities is 
complex and multifaceted, with several contributing factors including the age of the 
patient, general decrease in performance status, and comorbidities. The patient and family 
support system may also contribute to limited access of older patients to chemotherapy.  
Patient health beliefs and attitudes can influence the healthcare practitioner treatment 
behavior.  The type of healthcare facility is among other contributing factors affecting 
patient treatment.  Developing trials specifically for the elderly and enrolling a diverse 
racial/ethnic mix into clinical trials are needed to improve the understanding in treatment 
differences.  Based on findings of the present analysis, additional research is needed into 
treatment differences according to patient age, geographic location, and compliance to 
clinical treatment guidelines. In addition, future research should include patient 
performance status; lifestyle factors, such as smoking status; and co-morbidities as these 
influence patient treatment decisions. 
 Given the findings of this study, further prospective research evaluating specific 
reasons why a patient is not treated consistent with the NCCN guidelines is warranted.  Is 
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noncompliance to the guidelines the physician’s decision or lack of familiarity of the 
guidelines?  Physicians have been found to be noncompliant with guidelines cross a 
variety of medical specialties (Goldberg et al., 2015). Physician disagreement with the 
guidelines, risk versus benefit of treatment, and patient/family decisions not to receive 
recommended treatment have been found to influence compliance. However, it is 
unknown if treatment was recommended by the physician and the patient refused 
treatment, if the guideline treatment was offered to the patient, or for other reasons the 
patient refused treatment.  Additional research is needed on these factors focusing on the 
healthcare system as it remains unclear what effect treatment differences reflect 
individual patient decisions or healthcare system factors. 
 Oncology patient care is usually conducted with a team of physicians and 
healthcare professionals guided by clinical practice guidelines or past experience to 
provide the best care.  Cancer care should be collaborative or a two-way street between 
the healthcare professional and the patient.  Physicians have limited time to spend with 
each patient and having open communication with the patients and their families about 
treatment plan and goals, toxicities of treatment, and understanding patient/family goals 
and needs can improve outcomes.  Patients and family should be aware that the NCCN 
guidelines are available in lay persons terms, should become more involved in their own 
care and should be willing to have a discussion with their physician about their treatment 
goals.  If a physician doubts a patient’s commitment to recommended treatment, another 
easier treatment may be offered that is not in accordance to treatment guidelines (Martin, 
Williams, Haskard & DiMatteo, 2005).  Improving communication between the 
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physician and the patient has been shown to improve patient compliance to treatment 
(Zolnierek & Robin, 2009) 
 Accurate and complete race/ethnicity information needs to be captured within 
large databases and registries.  Encouraging patients, particularly African American and 
Hispanics to participate in clinical trials could help in furthering an understanding of 
treatment disparities on outcomes and is essential to formulate policy and design 
programs to address the disparities.  Additional education of healthcare professionals 
around disparities and a better understanding of different racial/ethnic beliefs and cultural 
differences are needed.  Breaking down racial/ethnic differences may influence treatment 
to the guidelines for the better.  Additional research is needed to gain an understanding of 
how treatment decisions are made within the healthcare system 
Implications 
Social Change 
 This research contributes to positive social change by providing support for a 
better understanding of factors that might influence treatment according to the NCCN 
guidelines.  Increasing an understanding of racial disparities in the quality of NSCLC 
care could help inform healthcare professional, policy makers, and public health 
professionals to focus on decreasing disparities and improving care and cancer outcomes.  
Basing public health initiatives, programs, research, and outcomes on evidence-based 
guidelines data could lead to better public understanding of disease and treatment.  
 Educating patients about the availability of treatment guidelines and empowering 
patients to take active roles in treatment decision process could go a long way to improve 
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quality of life and outcomes in cancer treatment. Healthcare professionals need to take an 
interest in what is important to the patient. While challenges to patient communication 
exist partially due to the complexity of the disease and treatment, healthcare professionals 
must continue to improve communication with patients and engage patients in their own 
care. 
Conclusions 
 In conclusion, the study findings revealed that race/ethnicity did not contribute 
significantly to treatment according to the NCCN treatment guidelines.  However, age at 
diagnosis was a consistent contributor across all groups. In addition, regional differences 
in treatment were found for some cancer patients.  These findings provide a rationale for 
the need to strengthen the clinical research in elderly lung cancer patients to understand 
the best treatments for these patients and ways to improve compliance to the NCCN 
clinical guidelines that might improve quality of life, outcomes to treatment, and help in 
guiding the eradication of lung cancer. Further research is warranted to understand 
physician lack of compliance to clinical guidelines and factors contributing to why 
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